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 Introduction  
1 Introduction 
1.1 The Structure of Bone 
 
The skeletal system is assembled of bones.  In addition with the cartilage, the bones serve 
three functions: a) metabolic, as a reserve of ions, especially calcium and phosphate, for the 
maintenance of serum homeostasis, which is essential to life; b) mechanical, support and 
site of muscle attachments for locomotion; and c) protective, for vital organs and bone 
marrow.   
Bone consists of two components, the cancellous and the cortical bone.  Cancellous and 
cortical bone is constituted of the same cells and the same matrix elements, but they are 
structurally and functionally different.  Cancellous bone, also named spongy or trabecular 
bone, is a network of thin, calcified trabeculae.  The spaces enclosed by these thin 
trabeculae are filled with hematopoietic bone marrow.  Cancellous bone is relatively 
prominent in the vertebral column, in the epiphysis, and the metaphysis of the long bones.  
Cortical bone is a thick and dense calcified tissue, which encloses the medullary cavity 
where the hematopoietic bone marrow is housed.  Cortical bone is the main component in 
long bone shafts of the appendicular skeleton and fulfils mainly the mechanical and 
protective function.  In the skeleton 80% of the bone is cortical bone, but cancellous bone is 
metabolically more active per unit volume and so the skeletal metabolism is approximately 
equally distributed (Eriksen et al., 1994).  It is demonstrated that cortical and cancellous 
bone behave differently and exhibit different responses to metabolic changes and treatments 
(Riggs et al., 2002) (Parisien et al., 1990) (Daci et al., 2000) (Poli et al., 1994) (Bikle et al., 
1990). 
Bone is built and resorbed by two different cell types: the osteoblasts and the osteoclasts.  
Osteoblasts are the bone-forming cells.  They build up the bone through the secretion of 
bone matrix components.  Osteoblasts originate from local mesenchymal stem cells.  They 
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are present in the bone marrow and differentiate through the influence of specific factors 
along the osteoblast differentiation pathway.  Two osteoblast-specific transcripts have been 
identified: one encoding core-binding factor alpha-1 (Cbfa 1), a transcription factor (Ducy 
et al., 1997), and the other encoding osteocalcin, a secreted molecule that inhibits osteoblast 
function (Ducy et al., 1996).  The osteoblasts are attached to the bone surface and produce 
type I collagen, are responsive to parathyroid hormone (PTH), and produce osteocalcin 
when stimulated by 1,25 dihydroxyvitamin D (Williams and Frolik, 1991) (Partridge et al., 
1981).  Osteoblasts never appear or function individually but are always found in clusters of 
cuboidal cells along the bone surface.  When osteoblasts get trapped in the bone matrix that 
they produced and which later becomes calcified they are called osteocytes.   
On the other hand bone is resorbed by osteoclasts.  They derive from hematopoietic cells of 
the monocyte/macrophage lineage, which fuse to giant multinucleated cells.  Osteoclasts 
are usually found in contact with a calcified bone surface.  Characteristic for the osteoclasts 
is that the zone of contact with the bone has a ruffled border with dense patches on each 
side (Baron et al., 1993) (Eriksen et al., 1994).  The osteoclasts synthesize and secrete 
lysosomal enzymes such as tartrate resistant acid phosphatase (TRAP), and cathepsin K, 
and also metalloproteinases such as collagenase and gelatinase.  The differentiation of 
osteoclasts is dependent on the expression of two factors; the macrophage colony-
stimulating factor (MCS-F) which is expressed by the macrophages or osteoclasts itself 
(Udagawa et al., 1990), and receptor for activation of nuclear factor kappa B ligand 
(RANKL) which is expressed by osteoblastic lineage cells and activated T lymphocytes 
(Figure 1.1).  The signaling receptor (RANK) is located on the surface of osteoclastic 
lineage cells and their precursors (Lacey et al., 1998), (Kong et al., 1999).  Osteoprotegerin 
(OPG) functions as a secreted inhibitor of the RANK signaling pathway by binding to 
RANKL and competitively inhibiting the RANKL/RANK interaction on osteoclasts and 
their precursors (Simonet et al., 1997).   
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Figure 1.1. Mechanisms of osteoclastogenesis. Osteoclastogenic molecules such as PTH up-regulate the 
expression of RANKL, M-CSF and OPG of the stromal cells and osteoblasts. The binding of RANKL and M-
CSF with their receptors lead to the differentiation of the macrophage (osteoclast precursor) to osteoclast, a 
process inhibited by OPG. Adapted from Teitelbaum et al. 
 
 
Targeted deletion of OPG in mice results in an increase of bone resorption and severe, 
early-onset osteoporosis.  The early-onset osteoporosis in the OPG deficient mice is a result 
of an increased number of osteoclasts and an increased activity (Bucay et al., 1998). 
A shift in the balance of the activity of the osteoblasts and osteoclasts leads to an increase 
(osteopetrosis) or a decrease (osteoporosis) of bone mass.  The net loss of bone mass has 
been causally linked to estrogen loss.  It is believed that the main reason for the 
development of osteoporosis is the declining level of estrogen in postmenopausal women 
(Albright et al., 1941) and men (Khosla et al., 1998).  The decrease of circulating serum 
estrogen occurs in women in the fifth to sixth decade of life, when the ovaries stop to 
produce follicles.   
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1.2 The Synthesis, and Functions of Estrogens 
Estrogens belong to the family of steroid hormones.  The precursor for the steroid hormone 
synthesis is cholesterol, which is regulated by the adrenocorticotrophic hormone of the 
pituitary.  Multiple enzymatic steps lead from the cholesterol to the synthesis of the steroid 
hormones estrogens (Figure 1.2).  Estrogens consist of estrone (E1), estradiol (E2), and 
estriol (E3).  The estrogen formation is dependent on A-ring aromatization of its immediate 
precursor (Cole and Robinson, 1990) (Akhtar et al., 1982).  One of the precursors is 
testosterone which is converted to estradiol, by a particular isoform of the enzyme 
aromatase (see 1.5), which also catalyses the conversion of the androgen, androstenedione 
to the weak estrogen, estrone.   
Estrogens are the main female hormones and responsible for gender differences and 
reproduction.  In the first decade of life the release of gonadotropin hormones from the 
pituitary increases and leads to the production of estrogens from the ovaries.  During 
puberty estrogens initiate the development of the secondary sexual characteristics and start 
and maintain the menstrual cycle.  The aim of a menstrual cycle is to produce a mature 
follicle which is capable of reproduction.  From the puberty up to the fifth decade of life 
300-400 follicles reach maturity.  After that time there are no more follicles in the ovaries 
and the females stop to have reproductive cycles and to produce estrogen in the ovaries. 
In premenopausal women, more than 95% of serum estradiol and most of serum estrone is 
synthesized in the ovaries. 
In the recent years it was demonstrated that also extragonadal sites are capable to synthesize 
estrogens (Simpson et al., 2000) (Labrie et al., 1997a) (Khosla et al., 1997).  These 
extragonadal sites are the adipose tissue, brain, cardiovascular system, breast, and bone.  At 
the peripheral sites estrogens work in a paracrine or intracrine way (Labrie et al., 1998) 
(Labrie et al., 1997a).  Therefore, estrogens are not released into the blood stream.  They 
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Figure 1.2.  Pathway of steroid hormone biosynthesis from cholesterol.  Multiple enzymatic steps are 
necessary to convert cholesterol to androgens and estrogen.  The only enzyme which is indicated here is 
aromatase. 
 
initiate the response in the neighbor cells or in the cell which synthesized the estrogens.  
One example is the concentration of E2 present in breast tumors of postmenopausal women 
which is at least 20-fold greater than that present in the plasma (Pasqualini et al., 1996) 
(Castagnetta et al., 1996).  The paracrine or intracrine biosynthesis of sex steroids is 
economical because only the concentration required by the cells is synthesized, and the 
large dilution in the extracellular fluids that occurs after endocrine secretion is avoided.  
Labrie et al. (Labrie et al., 1997b) estimated that nearly all of the estrogen in 
postmenopausal women originates from extragonadal syntheses.   
The difference between the synthesis of estrogens in the gonads and the extragonadal sites 
(adipose tissue, brain, cardiovascular system, breast, and bone) is that as mentioned earlier 
the gonads use cholesterol as a precursor.  The cells from the extragonadal sites are 
dependent on circulating C19 androgenic precursors (androstenedione, testosterone), 
because they can not convert cholesterol into C19 precursors (Pasqualini et al., 1996) 
(Castagnetta et al., 1996).   
In general the estrogen action in the target tissues is mediated by estrogen receptor-α (ER-
α) and the estrogen receptor-β (ER-β) (see 1.3.1).  Estrogen receptors (ERs) are members of 
the nuclear receptor superfamily of transcription factors that can up- or down-regulate the 
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transcription of certain target genes.  The action of the ER occurs through targeting 
estrogen response element (ERE) on the target genes, by binding to coregulators, which are 
activators or repressors and recruit other transcription factors (Feng et al., 1998).  The 
coregulators can be broadly defined as cellular factors that are recruited by the nuclear 
receptors that complement the function of the receptors as mediators of the cellular 
response to endocrine signals.  Both coactivators and corepressors of nuclear receptor 
function have now been identified [for review see (McKenna et al., 1999)].  Perhaps the 
most important coactivators are the members of the steroid receptor coactivator (SRC) 
family (see 1.3.2).   
 
1.3 Estrogen Action on Bone – Role of Estrogen Receptors, and Steroid Receptor 
Coactivator (SRC) -1 
 
Estrogens play a critical role in regulating bone metabolism in women. Now there is also 
overwhelming evidence that estrogens are important also in the regulation of bone 
metabolism in men (Riggs et al., 2002).  Estrogens have an essential role in the pubertal 
growth spurt, skeletal maturation and in the acquisition of normal bone mass in females as 
well as males.  Lack of estrogens lead to a discordance between skeletal growth and skeletal 
maturation, and the accrual of bone density and mass.  Estrogens are known to be the major 
sex hormones involved in the maintenance of bone mass in the adult (Grumbach and 
Auchus, 1999) (Bilezikian, 1998) (Rochira et al., 2000).  Although knowledge of the action 
of estrogens on the adult skeleton is incomplete, a few actions have been elucidated.  
Estrogens suppress cytokine production and action (e.g. interleukin 6 and its receptor) in 
osteoblasts, decrease the rate of bone remodeling, promote apoptosis of osteoclasts, 
stimulate OPG by osteoblasts, and decrease apoptosis in osteoblast and osteocytes [see 
reviews (Karsenty, 1999) (Manolagas, 2000) (Mundy, 1999) (Kameda et al., 1997)].  The 
anti-apoptotic effect of estrogens on the osteoblast appears to involve the classical, genomic 
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and also the nongenomic action of estrogens.  The nongenomic action of estrogens involve 
the steroid receptors on the cell surface instead the intracellular nuclear receptors.  The 
nongenomic action is a rapid phosphorylation of extracellular signal-regulated kinases 
(ERKs), members of the mitogen-activated protein kinase family (Razandi et al., 2000) 
(Kousteni et al., 2002). 
Thus, the decrease of circulating estrogen levels after natural or surgical menopause is 
perhaps the single most important factor leading to osteoporosis in women and is initially 
associated with a high level of bone turnover (Turner et al., 1994).  Moreover, data from 
Khosla et al. (Khosla et al., 2002) now indicate that declining biologically available estrogen 
levels may be a major cause of “age-related” bone loss in men.  A commonly used therapy 
to treat meno- and postmenopausal bone loss and other clinical symptoms like hot flushes, 
night sweats, and increased risk of cardiovascular disease is the hormone replacement 
therapy (Lindsay et al., 1976; Lindsay et al., 1978).  Clinical and animal studies have 
demonstrated the beneficial effects of estrogens on bone, the vascular and central nervous 
system [for review see (Manolagas and Kousteni, 2001)].  However, since the findings of 
the Women’s Health Initiative (Rossouw et al., 2002), which have brought to light clear 
cardiovascular and breast cancer risks of at least combination therapy with oral conjugated 
estrogens and medroxyprogesterone a better understanding of estrogen action is clearly 
important both for defining better the mechanism(s) of bone loss in women and men, as 
well as for the development of new approaches to prevent or treat osteoporosis in both 
genders.  The cardiovascular and breast cancer risks could perhaps be minimized by the use 
of selective estrogen receptor modulators (SERMs) which can activate beneficial estrogen 
signaling pathways in bone and other tissues, without the adverse effects of estrogens on 
the breast and possibly the coagulation system.  The results from the Women’s Health 
Initiative also have led to an interest in lower-than-standard doses for menopausal estrogen 
therapy.   
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Of note, in recent years, the mouse is being increasingly used as a model to study 
mechanisms of bone loss and estrogen action on bone.  One reason is the availability of 
numerous inbred strains with differences in peak bone mass (Klein et al., 1998), (Beamer et 
al., 1996) and susceptibility to bone loss following ovariectomy (ovx).  In addition, a large 
number of genetically altered mice have been developed with important skeletal 
phenotypes, some involving defects in estrogen signaling pathways (Sims et al., 2003), 
(Modder et al., 2004).  Most of these mice have been bred into the C57BL/6 background 
strain. 
 
1.3.1 Effects of Estrogen Receptor-α versus Estrogen Receptor-β on Bone 
The biological effects of the steroid hormones are believed to be mediated by specific nuclear 
hormone receptors that demonstrate great specificity and high affinity for their respective 
steroid ligands under normal physiological conditions.  The following receptors: estrogen 
receptor-α (ER-α) and estrogen receptor-β (ER-β), androgen receptor (AR), and progesterone 
receptor (PR) are all members of the nuclear receptor superfamily class I as defined by 
Mangelsdorf (Mangelsdorf and Evans, 1995).  These receptors are characterized as ligand-
inducible transcriptional factors composed of a highly conserved modular structure of 
functional domains termed A-F, with the C domain responsible for binding to specific DNA 
sequence elements, and the E domain responsible primarily for ligand binding.  Also included 
within the receptor are regions involved in nuclear localization, dimerization, and 
transcriptional activation (Tora et al., 1989) (Webster et al., 1988) (Tasset et al., 1990).  The 
activation function-1 (AF-1) is located in the amino-terminal A/B domain, and activation 
function-2 (AF-2) is located within the E domain (Tzukerman et al., 1994) (Pham et al., 
1992).  The inactive receptor is in form of a large complex made up of loosely bound heat-
shock and other accessory proteins.  The steroid hormones are lipophilic, enter the plasma 
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membrane and the nucleus of the cells by diffusion and bind to the nuclear receptor.  After the 
binding of the steroid receptor, the receptor is activated and released from the heat-shock 
proteins.  The receptor-ligand complex interacts with an identical or a related receptor to form 
a homo- and/or heterodimer (Cowley et al., 1997) (Pace et al., 1997).  The homo- or 
heterodimer binds to specific cis-active elements in the promoter region of the target gene, 
resulting in transcription of the gene and ultimately leads to a cellular or tissue response.   
The two known receptors for estrogen, ER-α and ER-β share a great structural homology 
and the ligand binding affinity is similar, however, their transactivation domains, tissue 
distribution, and molecular sizes differ significantly.  The levels of the β species are high in 
prostate, ovary, brain and bladder, but are low or absent in uterus, kidney, pituitary, and 
epididymis - tissues which contain high levels of the α species (Kuiper et al., 1996) (Kuiper et 
al., 1997).  In certain cell systems, transfection-reporter gene responses indicate that ER-β is a 
weaker regulator of gene transcription than the extensively studied ER-α (Kuiper et al., 1996) 
(Kuiper et al., 1997) (Paech et al., 1997) and it has been shown that ER-α activates, whereas 
ER-β inhibits, AP-1 regulatory elements (Paech et al., 1997). 
Osteoblastic cells express both ER-α and -β, but both are differentially expressed during 
osteoblast differentiation, with ER-α concentrations increasing by almost 10-fold, whereas 
ER-β concentrations increase only slightly during differentiation of osteoblastic precursor 
cells into mature osteoblastic cells (Onoe et al., 1997).  Immunohistologic studies of 
developing human bone have demonstrated that whereas ER-α is the predominant species 
in cortical bone, ER-β is the major receptor present in cancellous bone (Bord et al., 2001).  
Similarly, ER-β appears to be present primarily in cancellous bone in the rat femoral 
metaphysis and spine, with much lower levels in the cortical bone of the femur (Onoe et al., 
1997). 
In humans, the importance of estrogens in bone is clearly demonstrated in the described 
cases of a defect in the estrogen receptor gene (Smith et al., 1994) and two cases of 
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aromatase deficiency (Mullis et al., 1997) (Carani et al., 1997) (Morishima et al., 1995), 
both resulting in a lack of estrogen action.  The patients had osteoporosis, unfused 
epiphyses, increased markers for bone remodeling and continuing linear growth in 
adulthood.  A treatment with estrogens led to a closure of the epiphyses and a dramatic 
increase of bone density in the patients with the defect of the aromatase gene.   
The skeletal phenotypes of the ER-α knock out (ERKO), ER-β knock-out (BERKO) and 
double ER-α and –β knock-out (DERKO) mice have also been analyzed in some detail.  
The caveat with the studies on the initial ERKO mouse is that the bones in this mouse 
expressed a splice variant of ER-α, which allowed partial responsiveness to estrogens 
(Denger et al., 2001).  Using a more complete knock out of ER-α, Sims et al. (Sims et al., 
2002) found that the ERKO mice had a decrease (not an increase) in bone turnover and an 
increase (not a decrease) in trabecular bone volume in both male and female animals.  
These surprising findings appeared to be due to markedly elevated testosterone and E2 
levels in the male and female mice, respectively.  Thus, the elevated testosterone levels 
likely activated androgen receptor signaling in the male ERKO mice and the elevated E2 
levels likely activated ER-β signaling in the female ERKO mice, demonstrating that these 
receptors, in the setting of elevated sex steroid levels, could compensate for loss of ER-α.  
Deletion of ER-β led to different responses in males, where bone was unaffected, and in 
females, where bone resorption was decreased and trabecular bone volume increased (Sims 
et al., 2002).  This suggested that in females, ER-β may antagonize the action of ER-α in 
bone, and was consistent with previous data demonstrating that the BERKO females have 
an increase in cortical bone associated with increased periosteal apposition that develops 
during growth (age 3-6 months) and is maintained in adults (age 12-13 months) (Ke et al., 
2001; Windahl et al., 2001).  The adult BERKO females also appear to be protected against 
the age-related cancellous bone loss that occurs in the wild type (WT) mice (Windahl et al., 
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2001) (Ke et al., 2001), suggesting either that ER-β is permissive for age-related bone loss 
in mice, or that loss of ER-β results in increased sensitivity to estrogens, thus perhaps 
compensating for the age-related decline in estrogen levels in the BERKO mice.  Finally, 
gene array analysis of bones from either WT, ERKO, or BERKO mice that were 
ovariectomized (ovx’d) and treated with E2 has demonstrated that loss of ER-β resulted in 
an 85% increase in the mRNA levels of genes stimulated by ER-α; in the absence of ER-α, 
ER-β was effective in stimulating estrogen-responsive genes, albeit to a reduced extent 
(Lindberg et al., 2003). 
Taken together, the collective findings from the ER-α-deficient human male, aromatase-
deficient males, and the mouse KO models would indicate that ER-α is likely the dominant 
ER mediating estrogen action on bone in female and male mice.  However, it does appear 
that, in the absence of ER-α, in female, but not in male mice, ER-β may be able to at least 
partially compensate for loss of ER-α (Sims et al., 2003).  Moreover, the physiological 
consequences of the higher ER-β levels in cancellous as opposed to cortical bone (Onoe et 
al., 1997) (Bord et al., 2001) are unclear at present. 
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1.3.2 Steroid Receptor Coactivator (SCR)-1 
SRC-1 is a member of the SRC family.  Besides SRC-1, which was the first nuclear 
receptor coactivator to be cloned (Onate et al., 1995) the SRC family include also SRC-2 
(Hong et al., 1996); and SRC-3 (Li et al., 1997).  The sequence similarity between SRC-1, -
2 and -3 is around 40%.  The most highly conserved region in the family is the N-terminal 
basic helix loop helix (bHLH)-PAS domain.  The bHLH region functions as a DNA-
binding or dimerization surface, and the PAS domain also plays a role in protein-protein 
interactions and dimerization (Figure 1.3).  The receptor interacting domain (RID) is 
located following the bHLH-PAS domain.  Detailed analysis of the sequence of the RID 
identified a conserved motif, LXXLL, where L stands for leucine and X stands for any 
other amino acid.  This conserved motif is termed the nuclear receptor (NR) box, which 
mediates interactions between the SRCs and liganded nuclear receptors.  Three such motifs 
are found in the RID of SRC coactivators.  The C-terminus of the SRC proteins contains the 
activation domain (AD), which interacts with general transcriptional activators, such as 
CBP/p300.  This region also contains a histone acetyltransferase (HAT) activity.  
Coactivators mediate the effects of transcriptional activator proteins, presumably by helping 
to recruit a complex of RNA polymerase II and associated basal transcription factors (a 
preinitiation complex) to the promoter or by activating a preinitiation complex that has 
already been assembled on the promoter (Figure 1.4) 
bHLH PAS-A PAS-B
RID
i  ii  iii
AD
iv v  vi Q-rich
RID
vii
HAT
 
Figure 1.3.  Schematic representation of the SRC family domain structure.  The N-terminus contains the 
highly conserved bHLH and PAS A/B domains.  The centrally located receptor-interacting (RID) and 
Activation (AD) domains each contain three LXXLL motifs, while SRC-1 contains an additional, non-
conserved motif at the C-terminus.  The C-terminus contains a glutamine-rich domain.  Also indicated is the 
domain containing the histone acetyltransferase (HAT) activity.  Adapted from Leo et al. 
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Of the three SRCs, SRC-1 and –2 appear to be the most closely related and able to 
potentially compensate functionally for each other.  SRC-3 appears to have a broader 
functional role than SRC-1 or –2, since in addition to facilitating the action of nuclear 
receptors; SRC-3 also enhances the transcriptional activity of a number of different 
activators, including interferon-α and CREB (Torchia et al., 1997).  Thus, for example, 
while microinjection of anti-SRC-1 antibodies into cells prevented retinoic acid receptor-
dependent transactivation of a retinoic acid response element-linked reporter gene, 
coinjection of a SRC-2 (but not SRC-3) expression vector could rescue transactivation of 
this reporter gene (Torchia et al., 1997). 
It is now appreciated that the relative balance of receptors, coactivator, and corepressor 
proteins is a critical determinant of the ability to initiate gene transcription. Since the relative 
concentrations of these molecules are cell specific, sex steroid hormones can have vastly 
different functions in different tissues of the same organism.  Variations in the recruitment of 
coregulatory molecules also appear to be the mechanism by which selective estrogen receptor 
modulators (SERMs) produce their tissue-specific effects (Shang and Brown, 2002). 
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Figure 1.4.  Schematic representation of an ER-SRC transcription complex. 
AC: acetyl group bound to the histone complex (light blue symbol), ER: estrogen receptor (dimer), p300: 
transcriptional coactivator (histone acetyltransferase activity), PBP: transcriptional coactivator (PPARgamma-
binding protein), Pol II: RNA polymerase II protein complex, SRC: steroid receptor coactivator 
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The physiological importance of SRC-1 for estrogen action has been demonstrated by the 
generation of SRC-1 KO mice (Xu et al., 1998).  The mice were generated by conventional 
gene targeting.  The targeting event inserted an in-frame stop codon at the Met381 in exon 4 
causing a downstream deletion of genomic sequence.  The SRC-1 functional domains were 
disrupted.   
The homozygous mutants are viable and fertile in both sexes, but exhibit significant resistance 
to estrogen action in a number of tissues, including the uterus and mammary gland.  Xu et al. 
(Xu et al., 1998) also tested whether the endocrine feedback control systems of the SRC-1 KO 
mice was affected.  Therefore, they measured E2, and testosterone concentrations in serum 
from age-matched wild type (WT) and SRC-1 KO mice.  The E2 and testosterone 
concentration in SRC-1 KO mice were 1.2 and 1.5 times those in WT animals, respectively.  
Of note, the expression of SRC-2 is increased in several tissues in these mice, suggesting that 
this related coactivator may be at least partially compensating for loss of SRC-1 function.   
In the presented study, I used SRC-1 KO female and male mice to characterize in detail the 
consequence of SRC-1 deficiency for E2 action on bone in vivo.  Recognizing that these mice 
have compensated estrogen resistance (Xu et al., 1998), I not only characterized their skeletal 
phenotype under basal conditions but also after gonadectomy and replacement with a 
physiological dose of E2.   
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1.4 Function of Androgen in Bone 
Like estrogens, androgens play an important role in skeletal metabolism, too.  Androgen 
deficiency results in a number of abnormalities of bone metabolism, such as lower peak bone 
mass and accelerated bone loss due to increased bone resorption, resulting in higher fracture 
risk, and a tall eunuchoid stature due to unfused growth plates (Orwoll and Klein, 1995).   
In men, androgens are produced by both the testes and the adrenal glands.  In women, the 
ovaries are the major source for androgens.  Androgens belong to the steroid hormones and are 
also synthesized from cholesterol (see Figure 1.2.).  Androstenedione is the precursor for the 
synthesis of testosterone, which is the major circulating adrenal androgen in both women and 
men (Orwoll, 1996).  Testosterone is bound to albumin and sex-hormone binding globulin and 
circulates through the bloodstream to the peripheral tissues, where it is converted by the 
enzyme, 5α-reductase, to the more potent 5α-dihydrotestosterone (5α-DHT).  In addition, 
testosterone, but not 5α-DHT, can be metabolized to estradiol by the enzyme aromatase (see 
1.5).   
Androgen action is mediated by androgen receptors (ARs) which have been identified and 
cloned.  During development, ARs are expressed in different reproductive and non-
reproductive tissues, including external and internal genitalia, mammary gland, adrenal glands, 
kidneys, muscles, pituitary gland, hypothalamus, and larynx.  The ARs were also detected in 
various bone cell types, including osteoblasts (Colvard et al., 1989), osteoclasts (Mizuno et al., 
1994), osteocytes, and heterotrophic chondrocytes (Abu et al., 1997).   
Besides the important control of bone turnover in older man by estrogens, a minor role is 
attributed to androgens (Falahati-Nini et al., 2000).  However, it was demonstrated that 
androgens influence the bone size and result in an increase of bone mass.  In male rats, 
furthermore, it has been shown that after castration, nonaromatizable androgen (5α-DHT) can 
prevent bone loss (Vanderschueren et al., 1992) (Wakley et al., 1991).  In the counterpart 
syndrome, testicular feminization syndrome, in which the androgen receptor in humans is 
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defect, bone density in these males is reduced (Marcus et al., 2000).  Affected rodents with 
these conditions have a cancellous bone volume and density similar to those in normal 
littermates; a finding attributed to high serum estrogen and estrogen precursor concentrations 
(Vanderschueren et al., 1994; Vanderschueren et al., 1993). 
In vitro, it was demonstrated that SRC-1 interacts with the ligand-activated AR (Bevan et 
al., 1999).  Here as well, one of the main functions of the SRC-1 protein is to recruit 
additional general transcription factors and to facilitate access of the basal transcription 
machinery to the promoter.  The transcription complex is able to initiate mRNA 
transcription of the target gene.  It seems that in the AR the N-terminal activation function-
1 (AF-1) domain is the most critical for transcriptional activation (Alen et al., 1999; Bevan 
et al., 1999).   
In vivo, the necessity of SRC-1 in mediating the function of androgens in bone is not clear 
yet.  Therefore, SRC-1 KO male mice were treated with testosterone or the nonaromatizable 
androgen, 5α-DHT, and changes of bone mass were determined by dual energy x-ray 
absorptiometry (DXA) and peripheral quantitative computed tomography (pQCT) 
measurements.  
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1.5 Aromatase 
As mentioned before the conversion from androstenedione to estrone and testosterone to E2 in 
the ovaries and also in the peripheral tissues is mediated by the enzyme aromatase.  This 
enzyme is complex and consists of two components: aromatase cytochrome P450 and, 
coupled to it, an ubiquitous flavoprotein, NADPH-cytochrome P450 reductase.  The heme 
protein is responsible for binding of the C19 androgenic steroid substrate and catalyzing the 
series of reactions leading to the formation of the phenolic A ring characteristic of estrogens.  
The aromatase complex is highly conserved among mammals and all vertebrates (Simpson et 
al., 2002).   
Aromatase cytochrome P450 is encoded by the single copy of the human CYP19 gene 
(Means et al., 1989) (Harada et al., 1990) (Toda et al., 1990).  CYP 19 consists of 10 exons 
with the coding region including only exon 2 through 10.  Untranslated exon 1 is a habitat 
of the promoter.  At least eight different exons 1 have been identified.  However, the 
protein expressed in various tissue sites is always the same.  For example placental 
transcripts contain at their 5´-end a distal exon, I.1 (Means et al., 1991).  By contrast, 
transcripts in cells of mesenchymal origin such as adipose stromal cells and osteoblasts 
contain the exon I.4 (Mahendroo et al., 1993).  Transcriptional regulation of CYP 19 is the 
major mechanism controlling the expression of aromatase, which is archived by tissue-
specific alternative splicing of the various exon 1.   
In humans, aromatase is expressed in a variety of tissues including the brain, placenta, 
adipose tissue, breast, ovaries and bone.  In bone the aromatase is expressed in osteoblasts, 
chondrocytes and osteoclasts (Purohit et al., 1992) (Sasano et al., 1997) (Jakob et al., 1997) 
(Nawata et al., 1995) (Schweikert et al., 1995).  So far in rodents the aromatase was just 
demonstrated in the ovaries, testis, and brain.   
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Recently, Eyre et al. (Eyre et al., 1998) were able to demonstrate the expression and activity 
of aromatase in rat osteosarcoma cells (ROS 17/2.8).  The mechanism responsible for 
regulation of aromatase expression in bone remains unclear.  In the presented experiments, 
the potential role of estrogens in aromatase regulation in bone tissue was investigated using 
bone cell cultures from human and rodents and bone tissue from rodents.   
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1.6 Aims of the Study 
Decades ago, Albright F. (Albright et al., 1941) related postmenopausal osteoporosis to 
estrogen deficiency and found that estrogens can improve the calcium balance of 
postmenopausal women.  Still pieces to complete the picture how estrogens regulate the 
development and maintenance of bone are missing.   
One aim of the present study is to systematically define the dose response of estradiol (E2) 
on bone and also to monitor the E2 effects on the uterus in C57BL/6 mice.  The effects of E2 
on different tissues are of great interest due to recent concerns about the treatment of 
postmenopausal women with estrogen replacement therapy.  A further aim is to define 
whether the E2 dose response in these tissues differs, depending on the particular 
experimental paradigm used.   
After defining the effect of different doses of E2 on bone and the uterus in general the next 
aim is to test the hypothesis that due to the presence of both estrogen receptor (ER) -α and –
β in cancellous bone versus the predominant expression of ER-α in cortical bone and a 
preferred interaction of steroid receptor coactivator (SRC)-1 with ER-α/β or ER-β alone the 
SRC-1 KO female mice have a defect in estrogen action in cancellous bone.   
Moreover, as a recent report found that ER-β plays no role in estrogen action on bone in 
male mice, I seek to demonstrate that there is a gender-related difference in estrogen action 
in cancellous bone.  Therefore, SRC-1 KO male mice are treated with E2 in the same way 
as the female SRC-1 KO and WT mice.  In addition I seek to establish the response of the 
cancellous and cortical bone to administrated androgen in SRC-1 KO male mice.   
In the last part of the presented work I test the hypothesis that aromatase, the enzyme that 
converts C19 precursors to estrogens, is expressed and active in human and rodent bone cell 
lines and rodent bone tissue and that the regulation of the enzyme is mediated by E2 itself.   
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2 Material and Methods 
All cell culture media, supplements and additional reagents were either purchased from 
Sigma Chemical Co. (St. Louis, MO) or GIBCO BRL (Grand Island, NY).  The tissue 
culture plastic ware was purchased from Corning (Corning, NY).  Molecular biology 
reagents and enzymes were purchased from Boehringer Mannheim (Indianapolis, IN) unless 
otherwise indicated. 
 
2.1 Cell Culture 
All human cell lines (hMS, SaOS2, hFOB-ER9, MG-63) were cultured in a humidified 
atmosphere of 5% CO2 in a phenol-free α modified essential medium (αMEM) supplemented 
with 10% heat inactivated fetal bovine serum (HI-FBS) and 1% Penicillin/Streptomycin 
(standard growth medium).   
After the experiments the RNA was isolated (see 2.2.1.1) from the differently treated cells 
and the expression of aromatase was examined by RT-PCR (see 2.3.2).   
 
The hMS cells are conditionally immortalized marrow stromal cells.  This cell line was 
established and characterized by Dr. Gori (Gori et al., 1999).  The hMS cell express an 
immortalized state at 33,5°C and a nonimmortalized state at 39°C, because of the transfection 
with a gene coding for a temperature-sensitive mutant of the SV-40 large T-antigen.  These 
cells can simulate the complete developmental sequence from undifferentiated precursors to 
cells with the complete osteoblast phenotype that are capable of forming mineralized 
nodules.   
First I differentiated the hMS cells for 0, 3, 7, 14 or 21 days at 39,5°C.  Therefore, the 
standard growth medium was supplemented with 10-8 M dexamethasone (Dex), 10-8 M 1α,25 
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dihydroxyvitamin D3 (1,25(OH)2D3), 10mM β-glycerolphosphate (βGP), and 100µM 
ascorbic-phosphate (Asc-P) (standard differentiation medium).   
To test if E2 regulates the expression of the aromatase, I cultured undifferentiated hMS cells 
with standard growth medium supplemented with 10% charcoal stripped serum (CSS) 
instead of HI-FBS for 24h.  This CSS is derived from plasma processed with charcoal to 
remove hormone proteins, to ensure that the measured effects result from the experimental 
treatment.  For another 24 h I cultured the hMS cells with 1% CSS together with ICI 182,780 
(10-7M).  ICI 182,780 (ICI, estrogen antagonist) is an analogue of E2 and acts by competing 
with E2 for binding to the ER.  Following the time of incubation I added vehicle, E2 (10-8M), 
IL-1β (10ng/ml), or ICI (10-7M) to the medium and incubated the hMS cell for another 24 h.   
 
The conditionally immortalized human fetal osteoblastic hFOB-ER9 cell line (this cell line 
was established earlier in cooperation with Dr. Spelsberg’s and Dr. Khosla’s laboratory and 
is now maintained in Dr. Khosla’s laboratory) containing physiological concentration of 
functional estrogen receptors were maintained at a temperature of 33,5°C.  To examine if 
these cells express estrogen receptor-α (ER-α) and if the deficiency or presents of E2 will 
change the expression of aromatase, I cultured the cells with standard growth medium 
supplemented with 10% CSS instead of HI-FBS for 24 h, in medium supplemented with 1% 
CSS plus ICI (10-7M) for another 24 h and were then treated with E2 (10-8M), or IL-1β 
(10ng/ml) for again 24 h.   
 
The human osteoblastic osteosarcoma cell line SaOS2 was maintained in standard growth 
medium at a temperature of 37°C.  During the experiment the standard growth medium was 
supplemented with 10-6 M Dex for 72 h and 10 ng/ml IL-1ß for the last 24 hours.  For the 
dose response experiment the cells were again grown in the standard growth medium 
supplemented with 10-6 M Dex for 72 h and 10 ng/ml IL-1ß for the last 24 hours and than 
treated with different doses of E2 (10-10- 10-7 M).  
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The rat osteosarcoma cell line ROS 17/2.8 has a more osteoblastic phenotype.  The rat 
osteosarcoma cell line UMR106 has a premature phenotype.  Both cell lines (ROS 17/2.8, 
and UMR106) were maintained in Ham’s F-12 medium (GIBCO BRL, Life Technologies, 
Grand Island, NY) supplemented with 10% HI-FBS and 1% Penicillin/Streptomycin.  All 
subsequent experiments were performed using this medium with or without additional 
reagents at doses and time indicated for each experiment.   
 
All the cell experiments were performed in 6-well plates in triplicate.   
 
Mr. Lamsam, a technician of Dr. Khosla’s laboratory, introduced me to the different cell 
lines which were used and stored in the laboratory.  In the past I had already worked with 
plant cell culture, hence, I was able to learn the handling of the human bone cells in a short 
period of time.  After the training time I was able to maintain the cell lines and perform the 
described experiments myself.  
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2.2 Molecular Biologic Methods  
2.2.1 Isolation of Total RNA  
2.2.1.1 Cells in vitro 
 
I isolated total RNA from cells in cell culture using the RNeasy Mini Kit (Qiagen, Inc 
Valencia, CA) following the manufacturer’s protocol.   
2.2.1.2 Rodent Bones 
Dr. Sanyal introduced me to the RNA isolation protocol and the freezer mill (SPEX 
CertiPrep, Metuchen, NY), so that I was able to perform the here described experiments 
myself afterwards.   
Total RNA from the rodent bones was isolated from the lumbar vertebrae (L1-L4) and the 
mid-shaft of the femur.  The metal tubes from the freezer mill (SPEX CertiPrep, Metuchen, 
NY) were cooled down in liquid nitrogen or on dry ice.  The frozen bones were placed into 
the metal tubes and ground in the freezer mill for 1 minute together with 1 ml Trizol 
(Invitrogen™ life technologies, Carlsbad, CA).  After the grinding the pulverized bone was 
transferred into a 50 ml sample tube (Corning, Corning, NY) and 4 ml Trizol was added.  
The frozen Trizol and the pulverized bone thaw in the additional Trizol and were incubated 
for 1.5 h in a water bath at 37°C under permanent shaking.  Every 15 minutes the samples 
were vortexed and at the end of the incubation time centrifuged for 5 minutes at 3000 rpm.  
The supernatant was transferred into a 2.0 ml vial (Corning, Corning, NY) and per 1 ml of 
Trizol supernatant 0,2 ml of chloroform (24:1 chloroform/isoamyl alcohol) was added.  The 
samples were shook vigorously by hand for 15 seconds, incubated for 5 minutes at room 
temperature, and than centrifuged for 15 minutes at 12500 rpm at 4°C.  The upper colorless 
aqueous phase was transferred into a new 2.0 ml vial and 300 µl isopropylalcohol (2-
propanol)/500µl aqueous phase was added.  The samples were mixed well, incubated for 5-
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10 minutes at room temperature and centrifuged for 15 minutes at 14000 rpm at 4°C.  The 
supernatant was removed and the pellet was air dried for 3 minutes.  The RNA pellet was 
dissolved in 30 µl of RNase-free sterile water by incubation for at least 15 minutes at 58-
60°C.  All vials from one sample were pooled, brought up to a total volume of 200 µl, and 
400 µl equal volumes of phenol and chloroform (24:1 chloroform/isoamylalcohol) were 
added.  The samples were centrifuged briefly.  The aqueous phase was used and the 
phenol/chloroform step was repeated two more times.  At the end the aqueous phase was 
mixed with chloroform (24:1 chloroform/isoamylalcohol).  For the RNA precipitation 1/10 of 
3 M sodium acetate (RNase free) and two volumes of cold 100 % ethanol was added to the 
aqueous phase and mixed well.  For one hour or over night the samples were kept at -70°C.  
The samples were heated up to room temperature and centrifuged for 15 minutes at 14000 
rpm.  The pellet was washed with 70 % ethanol (~400 µl/vial) and dissolved in 30 µl of 
RNase-free sterile water by incubation for at least 15 minutes at 58-60°C.  After quantitation 
by UV absorption at 260 nm, 1 µg of the total RNA was used for the cDNA synthesis. 
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2.2.2 cDNA Syntheses 
I completed 1 µg of total RNA and 2 µl of Random Primer p(dN)6 (0.25 units) with sterile 
water to a volume of 12 µl.  After incubation at 65° C for 5 minutes, I mixed the RNA with a 
cocktail containing 5x RT AMV buffer, RNase inhibitor (20 U), dNTPs (2 mM) and reverse 
transcriptase RT AMV (25 Units, Roche Diagnostics GmbH, Mannheim, Germany).  The 
final volume was 20 µl.  The samples were incubated at 42° C for 2 hours.  The RT AMV 
was inactivated at 95°C for 5 minutes.  Thus, I diluted the cDNA mix 5-fold and used the 
cDNA for the PCR analysis (see 2.3.2 and 2.3.3). 
I also used the iScriptTM cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA) to 
synthesize cDNA; iScript is a modified MMLV-derived reverse transcriptase, optimized for 
reliable cDNA synthesis over a wide dynamic range of input RNA.  The enzyme is provided 
pre-blended with RNase inhibitor.  The unique blend of oligo (dT) and random hexamer 
primers in the iScript Reaction Mix works exceptionally well with a wide variety of targets.  
This bled is optimized for the production of targets < 1 kb in length.   
I used a total volume of 20 µl for this reaction.  1µg of total RNA was mixed with 4 µl of 5x 
iScript Reaction Mix, 1 µl iScript Reverse Transcriptase, and nuclease-free water.  First the 
reaction was incubated at 25°C for 5 minutes, than at 42°C for 30 minutes.  The iScript 
Reverse Transcriptase was inactivated through an incubation at 85°C for 5 minutes.  Thus, 
the cDNA mix was then diluted 5-fold and used as a source of template for the PCR analysis 
(see 2.3.2 and 2.3.3). 
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2.3 PCR-Reactions 
2.3.1 Used Oligonucleotides 
I selected and ordered the necessary oligonucleotides for the PCR reactions.  The synthesis of the 
oligonucleotides was carried out by the Mayo Syntheses Group.  The oligonucleotides are dissolved 
in autoclaved, bidestillated water and stored at -20°C.   
Oligonucleotides for the cDNA amplification are: 
mSRC-1: A) 309 bp  B) 687 bp 
A) 5’-CAACCAGCAAAGGCTGAGTCCA-3’ and  5’-AGTACCTCCTGAGGGGTTAGAG-3’  
B) 5’-TGCCGACGCGCTAGACGATTTC-3’  and  5’-ACACAGCAAAGAACTGGAGGTG-3’ 
mSRC-2:  338 bp 
5’-CTACCAGCAGCCATGAGCAATC-3’  and  5’-CATCGACACACTGATGTTCATGTTG-3’ 
mER-α:  306 bp 
5'-GGCAAAGAGAGTGCCAGGCTTTG-3'  and  5'-CAGAAACGTGTACACTCCGGAATT-3' 
mER-β:  300 bp 
5'-GCAGCACAAAGAATATCTGTGTGTG-3'  and  5'-AGCGTGTGAGCATTCAGCATCTC-3' 
 
GAPDH 
Mouse and Rat: 239 bp 
5'-CATCACCATCTTCCAGGAGCGAG-3'  and  5'-GTGCAGGATGCATTGCTGACAATC-3' 
 
Aromatase:  
Human: 542 bp 
5'-GAGAAGTCTGTCAAGGATTTGAA-3'  and  5'-CCTATAAGGAACATTCTTTG CAA-3' 
Mouse: 247 bp 
5'-GAGTATCCAGAGGTCGAAGCAGCAA-3' and  5'-TACTCGAGCCTGTGCATTCTTCCGA-3'  
Rat: 339 bp 
5'-AGGAGAACGTGAATCAGTGTATA-3'  and  5'-TACTCGAGCCTGTGCATTCTTCCGA-3'  
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2.3.2 Conventional Polymerase Chain Reaction 
For conventional PCR a total volume of 50 µl consists of: 
 
5 µl 10x PCR Buffer 
1 µl 10 mM dNTPs 
1 µl (10 pmol/µl) forward primer 
1 µl (10 pmol/µl) reverse primer 
1-2 units  DNA Polymerase (Roche Diagnostics Corporation, Indianapolis, IN) 
5 µl cDNA (see 2.2.2) or genomic DNA 
x µl bidestillated water 
 
The amplification was performed in a Perkin Elmar Gene Amp PCR System 9600 with the 
following incubation times and temperatures: 
94°C 5 min initial denaturation step 
94°C 5 min denaturation of double strain DNA 
60-62°C 1 min hybridization of the primers with the template DNA 
(30 -35 x) 
70°C 1 min elongation 
70°C 5 min 
The hybridization temperature was dependent on the primer pair which was used in the 
reactions.  The time of the elongation and the cycle number was dependent on the length of 
the PCR product.   
After the reaction 1/10 of stopping buffer was added to the PCR product and was analyzed on 
an ethidiumbromid-agarose gel.  For the documentation the gel was monitored on an UV 
light table.  
I performed all conventional PCR reactions of the different cell lines and bone tissues 
myself.   
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2.3.3 Real Time Polymerase Chain Reaction 
Unlike with conventional PCR the real time PCR offers the possibility to quantify starting 
amounts of nucleic acid in individual reactions quickly and accurately.  The real time PCR 
machine is designed to detect fluorescent reporter molecules that increase in signal with each 
successive round of amplification.  A visual representation of the increase of fluorescent 
signal allows to determine starting amounts of nucleic acid in each sample, as well as to 
monitor real-time kinetics of each amplification. 
The real-time PCR was performed in an I-Cycler (Bio-Rad, Hercules, CA).   
Dr. Sanyal introduced me to the handling of the I-Cycler.  The determination of the 
expression level of SRC-2 (see 3.2.1.7) was performed by Dr. Sanyal.   
 
A 50 µl PCR mix, contained  
25 µl      iQ SYBR Green Supermix  100 mM KCl,  
 40 mM Tris-HCl, pH 8.4,  
 0.4 mM of each dNTP,  
 iTap DNA polymerase,  
 6 mM MgCl2,  
 SYBR Green 1,  
 20 nM fluorescein,  
 stabilizers 
7.5 pmol forward primer (see 2.3.1) 
7.5 pmol reverse primer (see 2.3.1) 
5.0 µl      cDNA (see 2.2.2) 
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2.4 Activity Test to Determine Aromatase Activity 
2.4.1 Preparation of the Mouse Bones 
 
Three-month old C57BL/6 female mice were sham-operated or ovariectomized by the 
supplier (Charles River Laboratories, Wilmington, MA).  Fourteen days after the surgery I 
harvested the femur and the tibia with assistance by one of our technicians (Mr. Fraser).   
Six-month old SW female mice (Charles River Laboratories, Wilmington, MA) were used 
for an initial experiment (without surgery).  In these mice the femur and the tibia were 
harvested, too.  After resection, I flushed out the bone marrow with ice-cold isotonic saline 
and the bones were stored on ice until all bones were flushed out.  After the flush out I 
ground the bones in a liquid N2 cold mortar with 2.5ml of Krebs-Ringer phosphate buffer, 
pH7.4 (with a final androstenedione concentration of 100nM, NADPH 1mM, glucose 1mM).  
The tissue was ground until fine ivory-colored bone spicules remained.   
 
2.4.2 Incubation with 3H-Androstenedione 
I placed the ground bones in six-well plates.  The plates were incubated for 3h at 37°C in a 
humidified atmosphere of 5% CO2 in the presence of 1 µl of [1β-3H] androstenedione (3H-
1βA; specific activity 25,9 Ci/mmol; Perkin Elmer, Life Sciences Inc.,Bosten, MA) and 
stirred every 30 minutes.  I terminated the reaction by transferring the plates into an ice bath 
(4° C) for 15 minutes.  The blank samples contained the medium without bone.  
To demonstrate the specificity of the aromatase activity assay one sample of ground bones 
were treated with 4-hydroxyandrostenedione [4-OHA], an aromatase inhibitor.  This 
aromatase inhibitor down-regulated the expected activity of the aromatase.   
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2.4.3 Determination of Tritiated Water 
The standard assay of aromatase activity in mouse bone measures the release of 3H-H2O from 
3H-1βAndrostenedione during estrogen synthesis.  
All procedures were done on ice. I transferred the supernatant and the bone spicules into 50 
ml tubes (Corning, Corning, NY) and centrifuged for 5 minutes at 1300 rpm.  The 
supernatant was stirred with 3 ml Chloroform and centrifuged for 5 minutes at 1300 rpm.  
800 µl of the aqueous phase were mixed well and incubated with 2 ml of 2.5% activated 
charcoal in 1 x PBS.  To allow sufficient adsorption of free steroids, the samples were mixed 
again after 15 minutes. After centrifugation at 1000 rpm for 15 minutes, 800µl of the 
supernatant was mixed with 10ml Ultimate Gold (Packard, Meriden, CT). The radioactivity 
was counted in a LS 6000 IC scintillation counter (Beckman-Coulter, Fullerton, CA). 
 
I adapted the here described activity test for the determination of aromatase activity as 
published by Ackerman et al. (Ackerman et al., 1981) earlier.  I performed all the 
experiments using this method myself.   
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2.5 Maintenance and Care for Mice 
2.5.1 Housing 
 
Two female and one male SRC-1 KO mice were provided from Dr. J. Xu from Dr. B. 
O’Malley’s Laboratory at the Baylor College of Medicine, Houston, Texas USA to establish 
a breeding colony.  The generation of the SRC-1 KO mice has been described (Xu et al., 
1998), and the mice used in this study have been extensively back-crossed (for 7 or more 
generations) into the C57BL/6 background.  The generation and back-crossing of the SRC-1 
mice was already done in Dr. B. O’Malley’s laboratory. 
The mice for my dose response study (C57BL/6 mice) were purchased from an animal 
supplying company (Charles River Laboratories, Wilmington, MA).  They were ten-weeks of 
age and housed in our animal unit until they were old enough for the experiment and had 
time to adjust to the new environment. 
The animals were housed in a temperature-controlled room (22±2° C) with a daily light/dark 
schedule of 12 h.  During the experiment the animals had free access to water and were pair 
fed (approximately 28 gram per mouse per week) standard laboratory chow (Laboratory 
Rodent Diet 5001, PMI Feeds, Richmond, VA) containing 0.95% calcium.  The Institutional 
Animal Care and Use Committee approved all animal procedures. 
The general maintenance, care and cleaning of the mice and mice cages was performed by 
the animal care personal of the Mayo Clinic.  Especially Mr. Fraser, one of the technicians in 
Dr. Khosla’s laboratory, took care of the breeding of the SRC-1 KO mice and helped me 
organizing all mice for the different experiments; food control and pair feeding was done by 
me.   
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2.5.2 Genotyping of the SRC-1 KO Mice 
Pups from the SRC-1 KO mice were genotyped at 4-5 weeks of age by polymerase chain 
reaction (PCR) (see 2.3.2) as described previously (Xu et al., 1998).  For the genotyping, 
genomic DNA was isolated from tail biopsies, respectively, after overnight proteinase K 
treatment and ethanol precipitation (Qiu et al., 1997).  The genomic DNA was used for PCR 
to distinguish between wild-type (+/+), homozygous mutant (-/-), or heterozygous (+/-) mice.  
For the analyses four specific primers were used (Xu et al., 1998).  The paired primers P1 
(5’-caaccagcaaaggctgagtcca) and P2 (5’-agtacctcctgaggggttagag) detected a 309-base pair 
exon region that represents wild-type SRC-1.  Primers P3 (5’-tgccgacgcgctagacgatttc) and P4 
(5’-acacagcaaagaactggaggtg) detected a 687-base pair fragment which represents 
homozygous mutant SRC-1.   
The breeding and genotyping of the SRC-1 KO mice were carried out by Mr. Fraser, who 
works as a technician in Dr. Khosla`s laboratory.   
 
2.6 Determination of Bone Mineral Density 
2.6.1 Dual Energy X-ray Absorptiometry 
 
Dual energy x-ray absorptiometry (DXA) allows accurate and precise measurements of soft 
tissue and bone.  The instrument provides an excellent correlation to total ash weight (r = 
0.99), which is commonly used as a standard.  The source for the x-ray is a cone beam with 
stationary area detectors.  An advantage of the DXA is that low doses of x-ray energy are 
used for the examinations and also a fast measurement of BMD at multiple sites is possible.  
The results are reported in mg/cm2 for bone mineral density (BMD), and in mg for bone 
mineral content (BMC).   
It is to keep in mind that DXA is a projectional (two-dimensional) rather than a cross-
sectional method, it includes both cortical and trabecular components into the measurement.  
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For an adequate evaluation of the overall BMD status, both cortical and trabecular sites 
should be examined. 
In the presented study the Lunar PIXImus densitometer (DXA, software version 1.44.005, 
Lunar Corp, Madison, WI) was used.  A calibration of the machine was performed daily 
using the hydroxyl apatite phantom provided by the manufacturer.  To determine the BMD in 
the mice in vivo, they were first anesthetized with Avertin (2,2,2 tribromoethanol, 720 mg/kg, 
ip).  They were than placed on the animal tray in a prone position.  In this position, the whole 
body of the mouse can be scanned at the same time, only the head is partially outside the area 
scanned by the machine.  However, in all analyses, the bones of the skull were excluded.  
After scanning, regions of interest were identified for more specific analyses.  In this study I 
always evaluated the BMD of the lumbar spine and the whole femur.  In repeatedly scanned 
mice (with repositioning between scans), the coefficients of variation (CVs) for total body; 
lumbar, and femoral BMD were 4,9%, 2,7%, and 4,3%, respectively.   
After an introduction of the handling of the Lunar PIXImus densitometer, I performed all 
BMD measurements and subsequent data analysis myself.  I also anesthetized and positioned 
the mice for the scans. 
2.6.2 Peripheral Quantitative Computed Tomography (pQCT) 
Computed tomography (CT) was introduced by Hounsfield (Hounsfield, 1973, 1976) at the 
beginning of the 70s for medical imaging.  The absorption of x-ray by an object yields an 
absorption profile.  The raw data are corrected for dead time and beam hardening.  By 
mathematical folding of many absorptions profiles from different angular positions a cross 
sectional image can be calculated which represents the original object.  Each point of the 
image (voxel) corresponds to an attenuation coefficient with the dimension 1/cm. By 
calibration with phantoms of a specified hydroxyl apatite concentration the attenuation 
coefficients can be transformed to density values.   
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The pQCT bone scanner is a fully automated measuring system for the determination of bone 
density.  The detector-system consists of a series of miniature-semiconductor-crystals.  The 
scan is divided into two steps: scout view and CT-scan.  During the scout view the object is 
scanned in steps along the longitudinal axis.  The beam moves perpendicular to this axis.  
The computer screen shows a color-coded digital image similar to a x-ray image with bright 
areas for bone and dark areas for soft tissue.  The scout scan is used to determine the desired 
position of the measurement.   
During the CT-scan the x-ray beam passes the object perpendicular to the axis of the arm.  
After each transverse scan the gantry is rotated 12° which is the angular distance from the 
first to the last of the detectors for the CT-scan. 15 rotations of the gantry therefore cover the 
necessary angular range of 180°. 
The pQCT measures cortical and trabecular combined, but also distinguish between these 
two bone compartments.  It defines the volume rather than its two-dimensional projection.  
The results which are reported for BMD are true volume (mg/cm3) and are less influenced by 
bone size.   
For the pQCT measurements the mice were first anesthetized with Avertin (2,2,2 
tribromoethanol, 720 mg/kg, ip) and than placed in a supine position on the gantry of the 
Stratec XCT Research SA Plus using software version 5.40 (Nordland Medical Systems, 
INC., Fort Atkinson, WI).  The calibration of the machine was performed daily with the 
hydroxyl apatite phantom provided by the manufacturer.  The mice were positioned so that 
the total length of the femur and tibia were visible on the scout view.  The scout view speed 
was set at 15.0 mm/sec with a slide distance of 0.5 mm.  Once the scout view was completed, 
the reference line for the CT scans was set at the most proximal point of the tibia.  Slice 
images were set at 1.9 mm (proximal metaphysis of the tibia) and for the dose response study 
cortical bone was measured at the tibia-fibula junction.  The CT speed was set at 3 mm/sec, 
pixel size was 100 µm x 100 µm and slice thickness was 0.5 mm.  After scanning, the CT 
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slices were analyzed using peel mode 2, cortmode 1 and contour mode 1 to evaluate 
trabecular and cortical parameters.  To determine the cancellous bone the threshold was set at 
214 mg/cm3 and for cortical bone at 710 mg/cm3.  CV was 4.4% for the total tibial 
volumetric BMD. 
A technician of the Stratec Company explained the handling, functions and options of the 
pQCT.  He monitored some of the practice scans and help with the analysis.  Later, I 
performed all the scans described in this study myself, including intra-abdominal anesthesia 
and positioning of the mice. 
2.7 Micro computerized tomography (µCT) scanning  
In addition to pQCT scanning µCT scanning was used which provides a much higher spatial 
resolution and therefore reduces the volume render effect.  The µCT made it possible to 
analyze the bone specimens in more detail.  The specimen is placed on a sample table and is 
rotated in 721 equiangular steps around 360° between an exposure with X-ray and the 
recording by a charge-coupled device (CCD) detector.  It allows non-invasive imaging and 
analysis of the three-dimensional bone structure.   
The whole tibia was scanned using a µCT system (Physiological Imaging Research 
Laboratory, Mayo Clinic, Rochester, MN, Principal Investigator: Dr. Ritman) as described by 
Jorgensen et al. (Jorgensen et al., 1998) with a resolution of 20 µm in all three dimensions.  
The raw data were reconstructed and the resulting 3-D images were displayed using image 
analysis software (Analyze® 4.0; Biomedical Imaging Resource, Mayo Clinic, Rochester, 
MN).  The volume of interest was 30 slices below the growth plate and covered 0.6 mm of 
the proximal metaphysis of the tibia.  This region was chosen because it allowed for 
measurements of cortical and cancellous bone and it represents the comparable region that 
was measured by pQCT.  Cortical thickness was measured at nine equally distributed sites at 
every second cross-section within the volume of interest. The full width half max function 
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was used for this measurement.  The trabecular bone volume was also measured in the same 
volume of interest.  To determine trabecular bone a threshold was chosen which represented 
bone in all samples.  Thus, every voxel with a grey scale above the threshold was trabecular 
bone and every voxel with a grey scale below the threshold was determined as marrow 
within the cortical shell. 
The positioning and scanning of the isolated tibias was done by technicians of Dr. Ritman’s 
laboratory (Physiological Imaging Research Laboratory, Mayo Clinic, Rochester, MN). The 
3-D-reconstruction of the raw data was performed by a technician who is specialized for this 
work.  I analyzed the resulting 3-D data sets for cancellous and cortical bone volume and 
thickness using Analyze® 4.0 (Biomedical Imaging Resource, Mayo Clinic, Rochester, MN). 
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2.8 Gonadectomies 
Before naturally occurring menopause 95% of serum estradiol (E2) and most of estrone (E1) 
is derived from ovarian secretion.  The remaining 5% come from peripheral conversion of 
steroid precursors.  In men 95% of circulating androgen is derived from testicular secretion.  
To create comparable steroid hormone levels in mice, the gonads which produce the majority 
of the sex steroids were removed, and resulted in estrogen or androgen deficiency.  Slow 
steroid release pellets (Innovative Research of America, Toledo, OH) were used to replace a 
defined concentration of steroid hormone levels in the mice.   
2.8.1 Ovariectomy 
For the ovariectomy the mice were anesthetized and prepared for the surgery, and a dorsal 
midline skin incision was made caudal to the posterior border of the ribs.  Using blunt 
dissection to tunnel subcutaneously, lateral to the skin incision, the muscles of the posterior 
abdominal wall were separated in order to enter the abdominal cavity.  The ovary was located 
in a fat pad just beneath the muscles.  Using forceps, the periovarian fat was gently grasped 
to lift and exteriorize the ovary.  Mosquito forceps were used to crush the fallopian tube and 
cranial-most part of the uterine horn distal to the ovary, being careful not to crush or contact 
the ovary.  The ovary was removed by cutting above the clamped area.  The uterine horn was 
returned into the abdomen, and the process was repeated on the other side. The skin incision 
was closed using wound clips.  Following the surgery, the mice were inspected every day for 
the first  week.  The wound clips were removed 7-10 days after the surgery. 
Because of the large number of animals and the time consuming nature of the procedure Mr. 
Fraser assisted me with all the ovariectomies; post-surgical animal care and the removel of 
the wound clips was done by me.   
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2.8.2 Orchidectomy 
For orchidectomy (orc) the mice were anesthetized and then placed in a supine position on a 
sterile working area.  A small 1.0 cm median incision was made through the skin at the tip of 
the scrotum.  The cremaster muscles were opened with a small 7 mm incision.  The testicular 
fat pad on the left side was localized and pulled it through the incision using a blunt forceps. 
The caudal epididymidis was pulled out together with the testis, followed by the caput 
epidpidymidis, the vas deferens and the testicular blood vessels. A single ligature was placed 
around the vas deferens and the blood vessels. The testis was removed and the procedure was 
repeated for the other testis.  After both testes were removed, the remaining pieces of the vas 
deferens, the fat and the blood vessels were replaced back in the scrotal sac.  The muscle 
layer was closed by using a resorbable 6-0 suture and the skin with non-resorbable 4-0 suture 
material.  Following the surgery, the mice were inspected every day for the first  week.  The 
non-absorbable suture material was removed 7-10 days post-operative.  
Similar to the earlier described ovariectomies Mr. Fraser also assisted me with all the 
orchidectomies because of the large number of animals and the time consuming nature of the 
procedure; again post-surgical animal care and the removel of the non-absorbable suture 
material was done by me. 
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2.9 Pellet Implantation 
For the implantation of the slow steroid release pellet (Innovative Research of America, 
Toledo, OH), the anesthetized mice were laid out on a sterile work area.  The animal was 
shaved between the shoulder blades and betadine applied to the shaved area.  A small 
incision was made with a surgical scissors, at which time a hemostat was inserted into the 
incision to create a small pocket under the skin.  The pellet was placed in the incision and 
sutured with 4-0 silk.  Also an additional skin clip was used to close the incision.  The skin 
clip was removed 7-10 days after the pellet implantation.  Following pellet implantation, the 
mice were inspected every day for the first  week.  If the pellet was coming out, it was 
noticed and that mouse was eliminated from the study.  Also, at the termination of the study 
after the mice have been euthanized, the skin between the shoulder blades was laid open and 
the remains of the pellet were identified.  The pellets were manufactured to last 60 days.   
After the surgery Mr. Fraser and I performed the pellet implantation together.  
2.10 Bone Histomorphometry 
At the end of the SRC-1 female study the lumbar spines (L1-L4) were collected and the 
dorsal side was marked to ensure the correct orientation of the samples at the time of 
embedding.  The lumbar spines were fixed in 70% ethanol for at least 72.  Subsequently, the 
specimens were dehydrated in 95% ethanol for 1 day and in 100% ethanol for 6 days.  The 
adjusting muscles were carefully removed from the spine so that the vertebral bodies are 
visible.  In the bone histomorphometry laboratory (Mayo Clinic, Rochester, MN, manager of 
the Mayo Bone Histomorphometry Lab: Dr. Sibonga) the lumbar spines were then embedded 
without demineralization in a mixture of methylmethacrylate-2-hydroxyethyl and 
methylacrylate 12.5:1 and sectioned at a thickness of 5 µm on a Reichert-Jung Supercut 2050 
microtome using tungsten-carbide tipped steel knives.  Dorsal spine sections were collected 
from the middle of the lumbar spine.  After clearing in xylene the sections were mounted in 
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Eukitt (ProSciTech, Thuringowa Central Qld, Australia) for microscopic examination.  All 
static cancellous measurements were performed on unstained sections under UV and normal 
light with the use of the Osteomeasure software, image analysis software programmed for 
measurements made specifically in bone (Osteometrics Inc., Atlanta, GA).  Cancellous bone 
was measured in secondary spongiosa in the spine.  The site did not include trabecular 
profiles immediately adjacent to cortical bone (to exclude peripheral modeling bone).  The 
measurements were performed in multiple frames, the sum of which totaled approximately 1 
mm2.  Histomorphometric measurements were obtained at the spine in order to correlate with 
the spine DXA measurements.  The measurements for cancellous bone included Bone 
Volume (Bone Volume/Measured Tissue Volume, BV/TV; %), Trabecular thickness (TbTh; 
µm), Trabecular separation (Tb.Sp.; µm), and Trabecular number (Tb.N,; mm-1).  The 
measured and calculated values for cancellous bone histomorphometry are measured, derived 
and expressed in standardized units and nomenclature for bone histomorphometry (Parfitt et 
al., 1987).  
However, since bone turnover in the vertebra is slower relative to the long bones. Bone 
formation rates (BFR) were determined in the various groups in the femoral metaphysis.  To 
determine dynamic parameters like BFR the mice received the fluorochromes calcein (10 
mg/kg dissolved in 1% sodium bicarbonate) and tetracycline (10 mg/kg dissolved in water) 
twelve and four days, respectively, before the end of the study.  The fluorochromes were 
injected into the tail vein of the mice, which were positioned in a mouse holder.  The 
fluorochromes incorporate at the calcification front of new forming bone.  When 
administered over a distinct labeling period, measurements of fluorochrome labels and the 
interlabel bone growth can be used to estimate bone turnover.  
The left femurs were processed in the same way as the lumbar spine with sections collected 
from the middle of the long bone.  After sectioned and mounted, the samples slides were 
examined under UV light.  The BFR (BFR/BS; mm2/mm/day) was measured in cancellous 
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bone at the proximal femoral metaphysis at a standard sampling site in secondary spongiosa.  
Only distinct, double fluorochrome labels were used for calculation of formation rates. 
I was trained in the different steps of bone histomorphometry sample preparation.  During the 
study I received additional help with the embedding and sectioning of the bone samples by 
technicians of the histomorphometry laboratory (Mayo Clinic, Rochester, MN, manager of 
the Mayo Bone Histomorphometry Lab: Dr. Sibonga).  After I was trained in the handling of 
the microscopes and the image analysis program by Dr. Sibonga, I performed all 
histomorphometric measurements and calculations myself.   
2.10.1 Goldner’s Masson Trichome Stain 
To assess whether a normal skeletal phenotype exists in the SRC-1 KO mice, longitudinal 
sections of the vertebral spine were stained with Goldner’s Masson Trichrome stain.  
Evidence of osteomalacia in the SRC-1 KO mouse bones was carefully examined since SRC-
1 may also modulate 1,25-dihydroxyvitamin D action.  
 
Weigerts A: Weigerts B:
2.5 gm  ferric chloride 1.25 gm hematoxylin  
1.0 ml  HCL 
Total volume of 100 ml with distilled water Total volume of 100 ml with 95% 
ETOH 
 
Ponceau de Xylidene-Acid Fuschin Stock Solution: 
0.6 gm  ponceau de xylidene G,R,2R (Acid Red 26) 
0.3 gm  acid fuschin 
0.9 ml  glacial acetic acid 
Total volume of 90 ml with distilled water 
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Orange G Stock Solution: 
1  gm  orange G 
Total volume of 100 ml with distilled water. 
 
Ponceau de Xylidene-Acid Fuschin-Orange G Staining Solution: 
10  ml  ponceau-acid fuschin stock soln. 
10  ml   orange G Stock soln. 
80  ml   distilled water 
 
1% Phosphomolybdic Acid: 
1 gm   phosphomolybdic acid 
Total volume of 100 ml with distilled water. 
 
Light Green: 
0.1 to 0.2gm   light green SF yellowish 
0.2 ml   glacial acetic acid 
Total volume of 100 ml with distilled water. 
 
First, the 5 µm sections were flattened with 50 % ethanol.  For the Goldner’s stain equal 
volumes of Weigerts A and Weigerts B solution were mixed and the sections were incubated 
in the Weigert Hematoxylin solution for 5 minutes.  The sections were rinsed in water until 
they were clear.  In the next step the sections were incubated for 3 minutes in the Ponceau de 
Xylidene-Acid fuschin-Orange G Staining solution and rinsed now with 1 % acetic acid until 
they were clear.  For 3 minutes the sections were stained in 1 % Phosphomolybdic Acid and 
than again rinsed in 1 % acetic acid.  In the last staining step the sections were incubated for 
3 minutes in Light Green.  Briefly, the sections for slide preparation were rinsed in 1 % 
acetic acid and subsequently rinsed in water and than dehydrated in increasing concentrations 
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of ethanol (70, 95, 100, and 100 %).  The sections were immersed in 50/50 % 
Xylene/Methanol and cleared in 100 % Xylene.  After clearing in Xylene the sections were 
mounted in Eukitt and were examined under the microscope.   
After training in Dr. Sibonga`s laboratory I was able to do all the stains, analyses and 
photographs described in this study myself.  
2.11 Uterus Histology 
At the end of the experiments the mice were sacrificed and the uteri were excised.  The tissue 
samples were fixed overnight in 10 % paraformaldehyde at 4°C, rinsed, and stored in 70 % 
ethanol before routine processing into paraffin wax.  The sections of the uteri were prepared 
and stained with hematoxylin-eosin. 
The uterus histology was performed by Dr. Frisk (Mayo Clinic). 
2.12 Estradiol Measurement 
Serum estradiol was measured by radioimmunoassay (RIA) (Diagnostic Products Corporation, 
Los Angeles, CA).  The DPC’s Double Antibody Estradiol procedure is a sequential 
radioimmunoassay in which the serum sample is preincubated with anti-estradiol antiserum.  
125I-labelded estradiol then competes with E2 in the sample for antibody sites.  After incubation 
for a fixed time, separation of bound from free 125I-labelded estradiol is achieved by the PEG-
accelerated double-antibody method.  Finally, the antibody-bound fraction is precipitated and 
counted.  The estrogen concentrations are read from a calibration curve.  The antiserum is 
highly specific for E2, with an extremely low crossreactivity to other naturally occurring steroids 
or therapeutic drugs that may be present in serum samples.   
The blood collection was performed by orbital sinus venipuncture in anesthetized mice.  After 
the blood was coagulated it was centrifuged for eight minutes at 8000 rpm to separate the serum 
from the cells.  The serum was stored at -20°C.  Before the radioimmunoassay procedure all 
components except the Precipitating Solution must be at room temperature (15-28°C).  As 
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controls some tubes were labeled with T (total counts), NSB (non-specific binding), A (maximal 
binding), and B through G to calculated the calibration curve.  100 µl of the zero calibrator A 
was pipetted into the NSB and A tubes, and 100 µl of each of the remaining calibrators B 
through G into correspondingly labeled tubes.  Also, 100 µl of each serum sample was pipetted 
into the prepared tubes.  50 µl of E2 Antiserum was added to all tubes expect NSB and T tubes.  
After vortexing everything well it was incubated for 2 hours at room temperature.  50 µl of 125I-
labelded E2 was added to all tubes and vortexed again.  The T tube was removed for the 
counting at the end, it requires no further processing.  The remaining tubes were incubated for 
one hour at room temperature.  Finally, 500 µl of cold Precipitating Solution was added to all 
tubes and vortexed.  An additional incubation for 10 minutes at room temperature was 
performed.  The samples were centrifuged for 15 minutes at 3000 x g.  The supernatant was 
decanted and all the residual droplets were removed.  Each tube was counted for one minute in 
the gamma counter.  All samples were prepared in duplicates.  The interassay CV is < 16%. 
The estrogen measurements were performed by Mrs. Hoey, a technician of Dr. Khosla’s 
laboratory.   
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2.13 Experimental Design 
2.13.1 Estrogen Dose Response Study 
 
Experiment 1.  The first experiment was been done in 6 month old female C57BL/6 mice 
(average body weight 0.028 kg).  The mice were assigned to seven groups (n= 6-12 per group) 
as follows: sham operated, ovx’d and implanted a vehicle pellet (0 µg/kg/day E2), or ovx’d and 
implanted with 60 day slow release pellets delivering 5, 10, 20, 40, or 500 µg/kg/day E2 
(Innovative Research of America, Toledo, OH) (see 2.8.1 and 2.9).  Following 56 days of 
treatment, bone mineral density (BMD) was measured at the spine and femur using dual energy 
X-ray absorptiometry (DXA, see 2.6.1) and at the proximal tibial metaphysis and the tibia-
fibula junction using peripheral quantitative computed tomography (pQCT, see 2.6.2).  After 
appropriate anesthesia, blood was drawn by cardiac puncture and the animals were sacrificed 
by inhalation of CO2.  The uterus was excised and weighed. 
Experiment 2.  In the second experiment, 3 month old C57BL/6 mice were used and the 
duration of the experiment was reduced to 1 month (average body weight 0.025 kg).  The 
rationale for this was that if similar results were observed in younger mice treated for a shorter 
period of time that would be preferable for future studies, given the cost of animal care and 
maintenance.  These mice were assigned to six groups (n= 4-7 per group) and were either sham 
operated, ovx’d and implanted a vehicle pellet (0 µg/kg/day E2), or ovx’d and implanted with 
60 day pellets delivering 5, 10, 20, or 40 µg/kg/day of E2 (Innovative Research of America, 
Toledo, OH) (see 2.8.1 and 2.9).  BMD was measured by DXA and pQCT (see 2.6.1, 2.6.2) 
after 30 days of treatment, the animals were sacrificed by inhalation of CO2, and the uteri were 
excised and weighed. 
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2.13.2 Effects of Ovariectomy and Estradiol Treatment on the Skeletal Phenotype of 
SRC-1 KO Female Mice 
 
In order to compare the skeletal response to estrogens in WT versus the SRC-1 KO mice, three 
month old female SRC-1 KO and WT littermates had baseline measurements of BMD 
performed by DXA (lumbar spine and femur) and pQCT (proximal tibia) (see 2.6.1 and 2.6.2) 
and were then divided into three groups (n = 8-11 mice per group).  Mice were assigned to the 
three groups based on the cancellous BMD measured by pQCT to assure comparable tibial 
BMD among groups at baseline.  Subsequently, the mice were either sham operated, ovx’d and 
implanted with a vehicle pellet (0 µg/kg/day E2), or ovx’d and implanted a 10 µg/kg/day E2 
pellet (0.015 mg/60 d pellets) (see 2.8.1 and 2.9).  On day 48 after the pellet implantation, the 
mice received the fluorochrome tetracycline (10 mg/kg) by tail vein injection followed by a 
calcein (10 mg/kg) injection on day 56 (see 2.10).  BMD was again measured by DXA and 
pQCT 60 days post-surgery.  Following this, the animals were sacrificed by inhalation of CO2 
and various tissues harvested.  The uterus was excised and weighed, and the lumbar spine (L1-
L4), tibias, and femurs were excised for histomorphometry (see 2.10) and µCT measurements 
(see 2.7). 
Subsequent to this initial experiment, a fourth group was added to both the WT and 
SRC-1 KO mice (n = 9-11 for each) in order to test whether the defects in estrogen action noted 
in the SRC-1 KO mice using an E2 dose of 10 µg/kg/day could be overcome using a high dose 
of E2.  These mice were ovx’d and received pellets delivering 40 µg/kg/day of E2 (see 2.8.1 and 
2.9).  In our preliminary dose finding study, this relatively high dose of E2 was clearly 
supraphysiological (see 3.1.1 and 3.1.2), but did not induce a sclerotic response in the tibial 
metaphysis, as has been seen with very high doses of E2 (Edwards et al., 1992).  All procedures 
in these mice were identical to those noted for the mice treated with the E2 dose of 10 
µg/kg/day. 
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2.13.3 Effects of Orchidectomy and Estradiol Treatment on the Skeletal Phenotype of the 
SRC-1 KO Male Mice 
 
This experiment was performed parallel to the experiment with the female SRC-1 KO mice.  
BMD was also measured at the beginning and at the end of the experiment by DXA and pQCT 
(see 2.6.1 and 2.6.2).  After the baseline measurement the three month old male SRC-1 KO 
mice and the WT littermates were assigned to three groups based on the cancellous BMD 
measured by pQCT to assure comparable tibial BMD among groups at baseline.  Subsequently, 
the mice were either sham operated, orchidectomized (orc’d) and implanted with a vehicle 
pellet (0 µg/kg/day E2), or orc’d and implanted a 10 µg/kg/day E2 pellet (0.015 mg/60 d pellets) 
(see 2.8.2 and 2.9).  On day 48 after the pellet implantation, the mice received the 
fluorochrome tetracycline (10 mg/kg) by tail vein injection followed by a calcein (10 mg/kg) 
injection on day 56 (see 2.10).  BMD was again measured by DXA and pQCT 60 days post-
surgery.  Following this, the animals were sacrificed by inhalation of CO2 and various tissues 
harvested.  The seminal vesicles was excised and weighed.  The lumbar spine (L1-L4), tibias, 
and femurs were excised but because of the clear results of the DXA and pQCT measurements 
the histomorphometry was not performed.  
 
 
2.13.4 Effect of Orchidectomy and Treatment with Androgens on the Skeletal Phenotype 
of the SRC-1 KO Male Mice 
To clarify if loss of SRC-1 in male mice has an impact of the action of androgens on bone, 
three month old orc’d WT and SRC-1 KO mice were treated with approximately 7 
mg/kg/day of testosterone, another group of orc’d mice were treated with 5,5 mg/kg/day of 
5α-DHT for 60 days.  Sham operated, and orc’d age-matched SRC-1 KO and WT littermates 
receiving a vehicle pellet (0 µg/kg/day) were used as controls (see 2.8.2 and 2.9).  The BMD 
was measured at the beginning and at the end of the experiment by DXA and pQCT (see 
2.6.1 and 2.6.2).  
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2.14 Statistical Analyses 
All data are presented as mean ± SEM.  The primary comparison in the SRC-1 KO 
experiments was between the WT, ovx’d plus E2, versus the SRC-1 KO, ovx’d plus E2, mice 
since the key question was the skeletal response to estrogen in the two groups of mice.  The 
sham and ovx’d plus vehicle groups were included in all cases to demonstrate that changes in 
the WT and SRC-1 KO mice were comparable under these conditions.  Overall comparisons 
within groups were made using ANOVA, and individual comparisons between groups were 
made using non-paired t-tests.  A P-value of < 0.05 was considered significant. 
I did all statistical analyses of the SRC-1 KO mice experiments which were double-checked 
by Mr. Peterson (mathematical assistant, Division of Endocrinology).   
For the dose response experiments all data are presented as means ± SEM.  The overall dose 
effect was tested by ANOVA.  Pair wise comparisons between the 0 dose versus the other 
doses were made using the Dunnett method, which adjusts for multiple comparisons.  The 
sham and ovx’d groups were compared using t-tests.  A P-value of < 0.05 was considered 
significant. I calculated all means and standard errors, all subsequent analyses using the 
Dunnett method was done by Ms. Atkinson (Division of Biostatistics, Mayo Clinic). 
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3 Results 
3.1 Estradiol Dose Response in Mice 
3.1.1 Effects of Increasing Doses of E2 on Bone and Uterus in 6 Month Old C57BL/6 
Female Mice Treated for 2 Months 
 
I initially compared the effects of increasing doses of E2 on bone and the uterus using ovx’d 
mice treated with 0, 5, 10, 20, 40, and 500 µg/kg/day of E2 for 2 months (see 2.13.1).  
Estrogen deficiency caused by ovx significantly decreased spine and femur BMD (Figure 
3.1) measured by DXA (see 2.6.1).  However, treatment with an E2 dose of as little as 5 
µg/kg/day was effective in preventing bone loss at both the spine and the femur in these mice 
(Figure 3.1).  Moreover, there was a dose-dependent increase in spine and femur BMD with 
higher doses (20 and 40 µg/kg/day) and even more so at a pharmacological E2 dose of 500 
µg/kg/day.   
Table 3.1 shows the values for volumetric BMD at the proximal tibial metaphysis (total, 
cancellous, and cortical) and the cortical volumetric BMD at the tibia-fibula junction as 
measured by pQCT (see 2.6.2) in the various groups.  In contrast to the spine (which also 
contains predominantly cancellous bone), cancellous BMD at the tibial metaphysis was not 
significantly lower in the ovx’d mice treated with vehicle as compared to the sham operated 
mice.   
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Figure 3.1. BMD of the spine and the femur (measured by DXA) in 6 month old female C57BL/6 mice 
following 56 days of either sham surgery or ovx plus pellets delivering 0, 5, 10, 20, 40, or 500 µg/kg/day of E2. 
Data are means ± S.E.M. *, P < 0.05 versus 0 µg/kg/day, adjusted for multiple comparisons by the Dunnett 
method; a, P < 0.05, b, P < 0.01 versus sham. 
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However, similar to the DXA measurements at the spine and femur, the 5 µg/kg/day dose 
was sufficient to increase (above the level of the sham mice) BMD at the tibial metaphysis.  
In fact, the overall dose response relationship at the tibia using pQCT was similar to that seen 
at the femur using DXA.  The high dose of E2 (500 µg/kg/day) clearly resulted in a sclerotic 
response at the tibial metaphysis, with a marked increase in bone mass (approximately 200% 
increase in cancellous BMD).  As expected, the high dose stimulated endosteal bone 
formation and increased cortical thickness (data not shown).  Cortical volumetric BMD was 
maintained at the level of the sham mice by an E2 dose of 5 µg/kg/day at the proximal site 
and the tibia-fibula junction of the tibia, with a further increase at higher doses (Table 3.1).   
Figure 3.2 shows the changes in uterine wet weight in these mice.  As expected, uterine 
weight decreased following ovx.  In contrast to the protective effects of very low doses of E2 
on cancellous and cortical bone, however, an E2 dose of 40 µg/kg/day was necessary to fully 
restore uterine weight in the ovx’d mice to the level of the sham mice (Figure 3.2).  Figure 
3.3 shows changes in uterine histology with the various doses of E2 in these mice (see 2.11).   
 
Table 3.1.  Volumetric BMD at the proximal tibial metaphysis (total vBMD, cancellous vBMD, and cortical 
vBMD) and at the tibia-fibula junction (cortical vBMD§) in 6 month old female C57BL/6 mice following 56 
days of either sham surgery or ovx plus pellets delivering 0, 5, 10, 20, 40, or 500 µg/kg/day of E2 measured by 
pQCT.  Data are means ± S.E.M.  *, P < 0.05 versus 0 µg/kg/d, adjusted for multiple comparisons by the 
Dunnett method; c, P < 0.001 versus sham. 
 
 
Total vBMD 
(mg/cm3) 
Cancellous 
vBMD (mg/cm3) 
Cortical vBMD 
(mg/cm3) 
Cortical vBMD§ 
(mg/cm3) 
Sham 
 434.67 ± 6.26 172.8 ± 3.52 887.71 ± 7.65 1139.46 ± 7.94 
Ovx +  
0 µg/kg/day 386.39 ± 5.64c 173.18 ± 5.76 851.48 ± 4.86c 1091.62 ± 6.94c
Ovx + 
5 µg/kg/day  518.63 ± 32.21* 280.11 ± 29.62 881.87 ± 14.32 1173.81 ± 17.90* 
Ovx + 
10 µg/kg/day 492.70 ± 28.88 246.01 ± 16.34 899.11 ± 10.13* 1152.57 ± 15.36* 
Ovx +  
20 µg/kg/day 517.85 ± 42.45* 266.82 ± 34.35 888.71 ± 12.74* 1159.06 ± 20.84* 
Ovx +  
40 µg/kg/day 607.76 ± 44.92* 352.76 ± 48.38* 902.79 ± 9.03* 1177.86 ± 10.94* 
Ovx +  
500 µg/kg/day 744.13 ± 53.68* 586.25 ± 59.46* 881.72 ± 8.61 1212.68 ± 185.89* 
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Figure 3.2. Uterine wet weights in 6 month old female C57BL/6 mice following 56 days of either sham surgery 
or ovx plus pellets delivering 0, 5, 10, 20, 40, or 500 µg/kg/day of E2. Data are means ± S.E.M. *, P < 0.05 
versus 0 µg/kg/d, adjusted for multiple comparisons by the Dunnett method; c, P < 0.001 versus sham. 
 
The uteri of sham operated mice show tortuous endometrium with tall columnar epithelium, 
large endometrial glands and the stroma had a significant infiltration with 
polymorphonuclear (PMN) cells (Figure 3.3.A).  By contrast the endometrium from the 
ovx’d mice had cuboidal epithelium, the endometrial glands were small, and the stroma 
contained closely packed hyperchromatic cells with no cytoplasm (Figure 3.3.B).  At a dose 
of 10 µg/kg/day, there was a shift from cuboidal to columnar epithelium.  Endometrial glands 
were getting larger again and contained a large amount of eosinophilic cytoplasm (Figure 
3.3.C).  However, a dose of 40 µg/kg/day was necessary to see tall columnar endometrial 
epithelium and stromal cells with abundant eosinophilic cytoplasm (Figure 3.3.D).   
Serum estradiol levels (see 2.12) decreased significantly after ovx (Table 3.2).  E2 treatment 
at doses of 5 to 20 µg/kg/day resulted in serum E2 concentrations similar to the level in the 
sham mice (with differences between these doses being hard to see due to the variability of 
even this sensitive assay at these low levels).  However, the 40 µg/kg/day dose did result in 
serum E2 levels that were approximately 4 times above the physiological level and even 
higher at the pharmacological E2 dose of 500 µg/kg/day (Table 3.2).   
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Figure 3.3. Uterine Histology.  At the end of the experiment the uterus from the mice was isolated and fixed in 
paraformaldehyde.  (A) Uterus from a sham mouse showing tortuous endometrium with tall columnar 
epithelium. (B) Uterus of an ovx’d mouse showing densely packed hyperchromatic cells within the stroma.  (C) 
Uterus of a mouse treated with 10µg/kg/day E2 showing columnar endometrial epithelium and hyperchromatic 
cells within the stroma.  (D) Uterus of a mouse treated with 40µg/kg/day E2 showing tall columnar epithelium 
and stromal cells with abundant eosinophilic cytoplasm.  The sections were stained with hematoxylin-eosin.  
Magnification x100. Histology was performed by Dr. Frisk.  Photographs were taken by Mr. Fraser.   
 
 
Table 3.2.  Serum estradiol concentration of 6 month old female C57BL/6 mice following 56 days of either 
sham surgery or ovx plus pellets delivering 0, 5, 10, 20, 40, or 500 µg/kg/day of E2.  Data are means ± S.E.M.  
*, P < 0.05 versus 0 µg/kg/day, adjusted for multiple comparisons by the Dunnett method; c, P < 0.001 versus 
sham.  Estrogen concentrations were measured by Mrs Hoey.  
 
  Serum E2 (pmol/L) 
Sham 19.86 ± 1.98 
Ovx + 0 µg/kg/day 11.71 ± 0.48c
Ovx + 5 µg/kg/day  18.13 ± 2.64 
Ovx + 10 µg/kg/day 18.65 ± 3.45 
Ovx + 20 µg/kg/day 14.61 ± 1.28 
Ovx +40 µg/kg/day 71.25 ± 28.49 
Ovx + 500 µg/kg/day 184.39 ± 88.43* 
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3.1.2 Effects of Increasing Doses of E2 on Bone and Uterus of 3 Month Old Mice 
Treated for 1 Month 
 
In the second experiment, I used a different experimental paradigm.  Three months old mice 
were treated for only 1 month (see 2.13.1).  As in experiment 1, the 5 µg/kg/day dose was 
effective at preventing bone loss at the femur (which contains predominantly cortical bone) 
in the younger mice in experiment 2 (Figure 3.4.).  Although the changes in cortical 
volumetric BMD at the tibia (proximal site and at the tibia-fibula junction) did not achieve 
statistical significance, the overall pattern was similar to that noted for the femur by DXA 
(Table 3.3).  By contrast to cortical bone, however, a higher dose (10 µg/kg/day) was 
necessary to prevent bone loss in these mice at the spine, which contains predominantly 
cancellous bone (Figure 3.4).  Similar to the findings at the spine, the 10 µg/kg/day dose was 
also necessary in the 3 months old mice in order to prevent loss of cancellous bone at the 
tibial metaphysis, although again, the individual changes in cancellous bone by pQCT were 
not significant (Table 3.3).  However, in contrast to the 6 months old mice treated for 2 
months, uterine weight was restored to the level of the sham mice even by the 5 µg/kg/day 
dose in the 3 months old mice treated for 1 month (Figure 3.5.). 
 
Table 3.3. Volumetric BMD at the proximal tibial metaphysis (total vBMD, cancellous vBMD, and cortical 
vBMD) and tibia-fibula junction (cortical vBMD§) in 3 months old female C57BL/6 mice following 30 days of 
either sham surgery or ovx plus pellets delivering 0, 5, 10, 20, or 40 µg/kg/day of E2 measured by pQCT.  *, P < 
0.05 versus 0 µg/kg/day, adjusted for multiple comparisons by the Dunnett method; c, P < 0.001 versus sham. 
 
  
Total vBMD 
(mg/cm3) 
Cancellous vBMD 
(mg/cm3) 
Cortical vBMD 
(mg/cm3) 
Cortical vBMD§ 
(mg/cm3) 
Sham 
 430.23 ± 4.85 216.26 ± 8.14 863.21 ± 8.15   1069.19 ± 8.10 
Ovx +  
0 µg/kg/day 375.08 ± 13.09 c 203.85 ± 5.06 836.65 ± 10.05   1050.10 ± 13.47 
Ovx +  
5 µg/kg/day 420.36 ± 23.35 201.20 ± 7.30 867.60 ± 15.02   1074.40 ± 13.10 
Ovx +  
10 µg/kg/day 464.16 ± 21.94 217.58 ± 9.17 868.54 ± 14.83   1077.60 ± 8.37 
Ovx +  
20 µg/kg/day 479.80 ± 34.46 233.88 ± 14.93 889.62 ± 18.01   1104.00 ± 14.60* 
Ovx +  
40 µg/kg/day 529.43 ± 80.67 276.27 ± 60.90* 882.03 ± 19.03   1096.78 ± 19.62 
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Figure 3.4. BMD of the spine and the femur (measured by DXA) in 3 months old female C57BL/6 mice 
following 30 days of either sham surgery or ovx plus pellets delivering 0, 5, 10, 20, or 40 µg/kg/day of E2. Data 
are means ± S.E.M. *, P < 0.05 versus 0 µg/kg/day, adjusted for multiple comparisons by the Dunnett method; 
a, P < 0.05 versus sham.  
Note the scale of the y-axis is the same as in Figure 3.1.  
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Figure 3.5. Uterine wet weights in 3 months old female C57BL/6 mice following 30 days of either sham 
surgery or ovx plus pellets delivering 0, 5, 10, 20, or 40 µg/kg/day of E2. Data are means ± S.E.M. *, P < 0.05 
versus 0 µg/kg/day, adjusted for multiple comparisons by the Dunnett method; b, P < 0.01 versus sham.  
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3.2 Characterization of the Skeletal Phenotype of the SRC-1 KO Mice 
The SRC-1 KO mice have been made available to Dr. Khosla’s laboratory by Dr. B. O’Malley 
to study the possible role of the SRC-1 coactivator in the skeletal response to E2 and androgens.  
Both male and female homozygote SRC-1 KO mice were fertile and showed growth rates 
similar to WT animals, with virtually identical body weights, bone dimensions, and BMD at 
various sites at 3 and 5 months of age (Figure 3.6).   
Moreover, as shown in Figure 3.7, the bones in the SRC-1 KO mice were histologically normal 
(see 2.10.1).  Importantly, there was no evidence in the SRC-1 KO mouse bones of 
osteomalacia or impaired mineralization, which is a significant point, since SRC-1 may also 
modulate 1,25-dihydroxyvitamin D action (Herdick and Carlberg, 2000) (Gill and Bell, 2000).  
In addition, Xu et al. (Xu et al., 1998) have noted that SRC-1 KO mice have modest elevations 
in serum E2 (~20%) and testosterone (~50%) levels as compared to WT mice.  These findings 
were confirmed in this study for serum E2 levels and, by measuring serum E2 levels through 
various phases of the estrous cycle in pooled serum from 4-8 female SRC-1 KO and WT mice.  
Also it was demonstrated that during diestrus, the SRC-1 KO mice had ~60% higher serum E2 
levels as compared to the WT mice (see 2.12).  These data provided further support to the 
hypothesis that the SRC-1 KO mice have compensated estrogen resistance in a number of 
tissues (Xu et al., 1998), including bone; the latter was studied in detail in the experiments 
described below. 
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Figure 3.6.  (A) Whole body BMD, (B) lumbar spine BMD, and (C) femur BMD (all measured by DXA) and (D) 
volumetric BMD at the proximal tibia (measured by pQCT) in WT and SRC-1 KO female mice at 3 and 5 months 
of age.  n = 8-11 mice per group. 
 55 
 Results  
 
Figure 3.7.  A, B:   Goldner’s Masson Trichrome stain of lumbar vertebrae at low power (intervertebral disc is 
at the center) (6 x) from WT (A) and SRC-1 KO (B) mice;  C, D:  Higher power view (25 x).  Note absence of 
any abnormal osteoid accumulation in the SRC-1 KO mice (D) compared to the WT mice (C), consistent with 
the absence of any mineralization defects in these animals;  E, F:  Fluorescent microscopy showing 
incorporation of crisp double labels of tetracycline and calcein (arrows), consistent with normal mineralization 
in the SRC-1 KO mice, similar to the WT mice.  
 
3.2.1 Effects of Ovariectomy and Estrogen Replacement on BMD in the Female 
SRC-1 KO Compared to the WT Mice 
3.2.1.1 DXA and pQCT 
 
To clearly define possible deficits in estrogen action in the female SRC-1 KO mice, I 
compared the effects of sham surgery, ovx with vehicle pellets, and ovx with E2 replacement 
(at a dose of 10 µg/kg/day) on BMD in WT versus SRC-1 KO mice.  The time of treatment 
was 60 days in this experiment, and BMD was measured at baseline and at the end of the 
experiment (see 2.13.2).  Figure 3.8.A shows the percent changes in spine BMD in the three 
groups of WT and SRC-1 KO mice.  As is evident, spine BMD decreased significantly 
following ovx in both the WT and SRC-1 KO mice.  However, whereas E2 treatment 
prevented this decrease in the WT mice, it was virtually ineffective in the SRC-1 KO mice.  
Similar findings were present at the femur, although here the deficit in E2 action did not 
appear to be quite as severe as at the spine (Figure 3.8.B). 
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Figure 3.8.  Percent changes in (A) lumbar spine and (B) femur BMD (both measured by DXA) in the WT and 
SRC-1 KO mice following sham surgery (open bars), ovx plus vehicle pellets (solid bars), or ovx and E2 pellets 
(shaded bars, 10 µg/kg/day) for 60 days.  The P-values for the main comparison (SRC-1 KO, ovx + E2, versus 
WT, ovx + E2) are as indicated.  ANOVA P-values for within group comparisons: spine WT, P = 0.001 and 
SRC-1 KO, P < 0.001; femur WT, P = 0.03 and SRC-1 KO, P <0.001.  **P < 0.01 and ***P < 0.001 for direct 
comparison with the respective sham group. 
 
 
Since the spine contains predominantly cancellous bone, whereas the femur contains both 
cancellous and cortical bone, I further explored whether the deficit in estrogen action in the 
SRC-1 KO mice was present predominantly in cancellous bone.  For this, I used the tibial 
BMD by pQCT, which can measure changes in cancellous and cortical bone combined, as 
well as separately in the two compartments.  As shown in Figure 3.9.A combined cortical and 
cancellous (total) tibial BMD decreased similarly in the WT and SRC-1 KO mice, and E2 
prevented this decrease in both groups, although it appeared to be somewhat less effective in 
the SRC-1 KO as compared to the WT mice.  However, as shown in Figure 3.9.B, similar to 
the spine DXA data, E2 was entirely ineffective in the cancellous compartment of the tibia in 
the SRC-1 KO mice, whereas it not only maintained, but modestly increased cancellous tibial 
BMD in the WT mice.  Moreover, as shown in Figure 3.9.C, estrogen effects on cortical 
BMD in the tibia were virtually identical in the WT and SRC-1 KO mice. 
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3.2.1.2 Micro-CT Analysis 
The above data using DXA and pQCT strongly suggested that the SRC-1 KO mice had a 
clear defect in estrogen action in cancellous bone, but preserved responses to estrogen in 
cortical bone.  To establish this more definitively, I performed detailed µCT analyses of the 
tibias (at the same site as used in the tibial pQCT measurements) using excised bones from 
the WT and KO mice (see 2.7).  Figure 3.10 shows an example of these scans from WT and 
SRC-1 KO mice, ovx’d and treated with E2, which are the key comparison groups.  As is 
evident from the middle and right panels (and consistent with the pQCT data at this site), 
estrogen treatment of ovx’d WT versus SRC-1 KO mice resulted in markedly altered effects 
on cancellous bone, with much more cancellous bone present in the WT compared to the KO 
mice.  By contrast, the amount of cortical bone present (seen best in the cross-sectional 
images in the right panels) was similar in the two groups following ovx and E2 treatment.   
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Figure 3.9.  Percent changes in (A) tibial total volumetric (B) tibial cancellous and (C) tibial cortical BMD (all 
measured by pQCT) in the WT and SRC-1 KO mice following either sham surgery (open bars), ovx plus 
vehicle pellets (solid bars), or ovx and E2 pellets (shaded bars, 10 µg/kg/day) for 60 days.  The P-values for the 
main comparison (SRC-1 KO, ovx + E2, versus WT, ovx + E2) are as indicated.  ANOVA P-values for within 
group comparisons: total tibia WT, P = 0.002 and SRC-1 KO, P = 0.003; cancellous WT, P < 0.001 and SRC-1 
KO, P = 0.322; cortical WT and SRC-1 KO, both P = 0.002.  *P < 0.05, **P < 0.01, and ***P < 0.001 for direct 
comparison with the respective sham group. 
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Figure 3.10.  Examples of µCT analyses of tibias from WT (upper panels) and SRC-1 KO (lower panels) mice, 
ovx’d and treated with E2.  The yellow band in the middle panels identifies the region of interest using a 
saggital section, and the right panels show cross-sectional images through this region.  Red indicates cancellous 
bone and arrows indicate cortical bone. 
 
 
This was more rigorously quantified in Figure 3.11.A.  As shown, cancellous bone volume 
(BV/TV) was significantly lower in the WT and SRC-1 KO mice following ovx as compared 
to the sham mice; however, whereas BV/TV was actually increased above levels in the sham 
mice in the WT, estrogen-treated mice, E2 treatment at a dose of 10µg/kg/day failed to 
preserve BV/TV in the SRC-1 KO mice.  By contrast, as shown in Figure 3.11.B, the pattern 
of changes in the ovx’d and ovx’d plus E2-treated mice in cortical thickness was very similar 
in the WT and SRC-1 KO mice, consistent with a preservation of estrogen action in cortical 
bone in the KO mice. 
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 60 
 
Table 3.4 shows the bone histomorphometry (see 2.10) data in the various groups.  
Consistent with the spine DXA measurements, BV/TV in cancellous bone in the spine was 
lower in both WT and SRC-1 KO mice following ovx.  However, whereas estrogen treatment 
preserved cancellous BV/TV in the WT mice, it failed to do so in the KO mice.  Similar 
results were seen with the other cancellous bone parameters (trabecular separation and 
trabecular number, Table 3.4).  The bone formation rate was significantly higher in the ovx’d 
WT and KO mice as compared to the respective sham groups; however, while estrogen 
treatment of WT mice reduced bone formation rate to even below that in the sham animals, 
the bone formation rate in the estrogen-treated SRC-1 KO mice was similar to that in the 
ovx’d SRC-1 KO mice and clearly different from that in the WT estrogen-treated mice. 
3.2.1.3 Bone Histomorphometry 
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Figure 3.11.  µCT analysis of tibias from WT and SRC-1 KO mice following sham surgery (open bars), ovx 
plus vehicle pellets (solid bars), or ovx and E2 pellets (shaded bars, 10 µg/kg/day) for 60 days.  (A) cancellous 
BV/TV and (B) cortical thickness.  The P-values for the main comparison (SRC-1 KO, ovx + E2, versus WT, 
ovx + E2) are as indicated.  ANOVA P-values for within group comparisons: BV/TV WT, P = 0.036 and SRC-1 
KO, P < 0.001; cortical thickness WT, P = 0.038 and SRC-1 KO, P = 0.06.  *P < 0.05, **P < 0.01, and ***P < 
0.001 for direct comparison with the respective sham group. 
BV/TV: Bone Volume/Measured Tissue Volume 
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 WT   SRC-1 KO
  
Sham 
 
Ovx + 
Vehicle 
 
Ovx + E2
 
ANOVA 
 
Sham 
 
Ovx + 
Vehicle 
 
Ovx + E2
 
ANOVA 
 
BV/TV (%) 
 
 
25.5 ± 2.4 
 
14.3 ± 0.8** 
 
23.3 ± 2.8 
 
0.01 
 
22.4 ± 1.7 
 
14.8 ± 1.6* 
 
15.6 ± 1.1**, a
 
0.004 
Trabecular 
separation (µm) 
 
 
157 ± 16 
 
249 ± 27* 
 
155 ± 24 
 
0.016 
 
162 ± 5 
 
257 ± 32* 
 
246 ± 15**, b
 
0.01 
Trabecular 
Number 
 
 
4.9 ± 0.4 
 
3.6 ± 0.3* 
 
5.2 ± 0.4 
 
0.015 
 
4.8 ± 0.2 
 
3.5 ± 0.4* 
 
3.5 ± 0.2,b
 
0.004 
BFR 
(µm3/µm2/d) 
 
 
0.14 ± 0.04 
 
0.26 ± 0.02** 
 
0.07 ± 0.01** 
 
< 0.001 
 
0.10 ± 0.02 
 
0.18 ± 0.04 
 
0.20 ± 0.02*,c
 
0.04 
lts  
 
 
 
 
 
Table 3.4.  Bone histomorphometric parameters in the WT and SRC-1 KO mice following sham surgery, ovx with vehicle pellet replacement, or 
ovx with E2 pellet replacement for 60 days.  P-values for the main comparison (SRC-1 KO, ovx + E2, versus WT, ovx + E2) are as follows: aP < 
0.05, bP < 0.01, cP < 0.001.  ANOVA P-values for within group comparisons are as indicated.  *P < 0.05, **P < 0.01 and ***P < 0.001 for direct 
comparison with the respective sham group.  BV/TV: Bone Volume/Measured Tissue Volume, BFR: Bone Formation Rate 
 
 Results  
3.2.1.4 Effects on Uterine Weights 
As shown in Figure 3.12, the dose of E2 used in this experiment was biologically meaningful, 
since it restored uterine weight in the ovx’d mice to near the level of the sham mice in the 
WT animals.  Interestingly, while this dose of E2 was clearly having at least partial effects on 
bone in the SRC-1 KO mice, particularly in cortical bone, it was totally ineffective at 
restoring uterine weight in the SRC-1 KO mice. 
 
3.2.1.5 Elimination of the Defect in Estrogen Action on Bone in the SRC-1 KO Mice 
Using High Dose Estrogen 
 
In order to establish that the defect in estrogen action in the SRC-1 KO mice was, in fact, due 
to estrogen resistance and that this could be overcome with a higher dose of E2, the WT and 
SRC-1 KO mice were also treated with a high dose (40 µg/kg/day) of E2 (see 2.13.2).  As 
shown in Figure 3.13 (and in contrast to the findings with the lower dose of E2 shown in 
Figure 3.8), a dose of 40 µg/kg/day of E2 resulted in virtually identical changes in spine and 
femur BMD in the WT and SRC-1 KO mice.  Thus, the defect in estrogen action present in 
the KO mice could be overcome using higher doses of E2. 
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Figure 3.12.  Uterine weights in the WT and SRC-1 KO mice following either sham surgery (open bars), ovx 
plus vehicle pellets (solid bars), or ovx and E2 pellets (shaded bars, 10 µg/kg/day) for 60 days.  The P-values for 
the main comparison (SRC-1 KO, ovx + E2, versus WT, ovx + E2) are as indicated.  ANOVA P-values for 
within group comparisons: WT, P = 0.002 and SRC-1 KO, P < 0.001.  ***P < 0.001 for direct comparison with 
the respective sham group. 
 62 
 Results  
******
%
 C
ha
ng
e 10
0
-10
20
A P=0.990
10
0
-10
WT SRC-1 KO
20
B
%
 C
ha
ng
e
*****
P=0.393
***
*
%
 C
ha
ng
e
%
 C
ha
ng
e
 
Figure 3.13.  Percent changes in (A) lumbar spine and (B) femur BMD (both measured by DXA) in the WT 
and SRC-1 KO mice following sham surgery (open bars), ovx plus vehicle pellets (solid bars), or ovx and high 
dose E2 pellets (shaded bars, 40 µg/kg/day) for 60 days.  Note that the sham and ovx groups are the same as 
shown in Figure 3.8.  The P-values for the main comparison (SRC-1 KO, ovx + E2, versus WT, ovx + E2) are as 
indicated.  ANOVA P-values for within group comparisons: spine WT and KO, both P < 0.001; femur WT, P = 
0.003 and SRC-1 KO, P < 0.001.  *P < 0.05, **P < 0.01 and ***P < 0.001 for direct comparison with the 
respective sham group. 
 
3.2.1.6 Comparison of Estrogen Receptor-α and Estrogen Receptor-β mRNA 
Expression Between Cancellous and Cortical Bone 
 
The group of T.C. Spelsberg has recently reported that in osteoblastic cells, SRC-1 seems to 
preferentially enhance (at least in vitro) the transcriptional activity of co-expressed ER-α  
and -β or the ER-β homodimer to a much greater extent than of ER-α homodimer (Monroe et 
al., 2003).  Since I had demonstrated what appeared to be a relatively selective defect in 
estrogen action in cancellous bone in the SRC-1 KO mice, I also compared the expression of 
ER-α and -β mRNAs in cancellous versus cortical bone by RT-PCR (see 2.3.2).  Total RNA 
was extracted from either the lumbar vertebrae (a site rich in cancellous bone) or from the 
mid-shaft of the femur (which contains exclusively cortical bone).  As shown in Figure 3.14, 
the expression of ER-α was similar in cancellous and cortical bone; by contrast, ER-β was 
only expressed in the cancellous bone of the lumbar spine, but not in the cortical bone of the 
femur shaft.  In addition, there was no obvious difference in the expression of either ER-α or 
-β in bones from the WT versus the SRC-1 KO mice.     
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3.2.1.7 Expression of SRC-2 in Bones of SRC-1 KO Versus WT Mice 
Since at least in some tissues (such as the brain and testis) expression of SRC-2 is 
upregulated in the SRC-1 KO mice and may partially compensate for loss of SRC-1 (Xu et 
al., 1998), also expression of SRC-2 in bones from WT and KO mice was examined using 
both conventional (Figure 3.15) (see 2.3.2) and real time RT-PCR (see 2.3.3).  The SRC-2 
mRNA was expressed in both the lumbar spine and femur shaft; however, there were no 
significant differences in the level of the SRC-2 mRNA in bones from the WT and SRC-1 
KO mice (Figure 3.15). By real time RT-PCR, the copy number for SRC-2 (per 100.000 
copies of GAPDH, n = 5 per group) was 1140 ± 188 (WT) versus 1440 ± 215 (SRC-1) in the 
spine (P = 0,324) and 2080 ± 206 versus 1720 ± 232 in the femur shaft (P = 0,279).  
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Figure 3.14.  Expression of ER-α and -β mRNA, assessed by RT-PCR, in the lumbar spine (a site rich in 
cancellous bone) and the mid-shaft of the femur (which contains exclusively cortical bone).  The expression of 
GAPDH mRNA indicated that the sample loading and amplification for each of the preparation was 
approximately the same.  40 PCR cycles were used. 
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Figure 3.15.  Expression of SRC-2 mRNA assessed by RT-PCR, in the lumbar spine and mid-shaft of the 
femur in the WT and SRC-1 KO mice.  The expression of GAPDH mRNA indicated that the sample loading 
and amplification for each of the preparation was approximately the same.  40 PCR cycles were used. 
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3.2.2 Skeletal Phenotype of SRC-1 KO Male Mice Under Basal Conditions 
Baseline measurements of the total, cancellous, and cortical volumetric tibial BMD, and the 
BMD of the spine, and the femur of the WT and SRC-1 KO male mice were not significantly 
different at 3 and 5 month of age (n = 9-10 animal per group) (Figure 3.16).   
 
3.2.3 Effects of Orchidectomy and Estrogen Replacement on BMD in the Male 
SRC-1 KO Mice Compared to the WT Littermates 
3.2.3.1 DXA and pQCT 
 
To investigate if the regulation of estrogen action on bone is gender specific, I treated 3 
month old male SRC-1 KO littermates of the female SRC-1 KO mice in parallel either with 
sham surgery, orchidectomy (orc) with vehicle, or orc with E2 replacement (10 µg/kg/day, 
body weight of 0,025 kg) with slow release pellets for 60 days.  The BMD was measured at 
baseline and at the end of the experiment (see 2.13.3).  As shown in Figure 3.17., after orc 
the percent change of spine and femoral BMD which was determined by DXA decreased 
significantly in both the WT and SRC-1 KO mice.  The dose of E2 was efficient to maintain 
the BMD at the spine (predominantly cancellous bone) (Figure 3.17.A), and the femur 
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Figure 3.16. Graph .(A) Whole body BMD, (B) lumbar spine BMD, and (C) femur BMD (all measured by 
DXA) and (D) volumetric BMD at the proximal tibia (measured by pQCT) in WT and SRC-1 KO male mice at 
3 and 5 months of age.  n = 9-10 mice per group. 
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(cancellous and cortical bone) in the WT mice and, in contrast to the female SRC-1 KO mice, 
also in the male KO mice (Figure 3.17.B).  There was no significant difference between the 
percent changes of the BMD in the WT versus the SRC-1 KO mice after the treatment.  The 
treatment with estrogen after orc resulted in identical responses of the SRC-1 KO and WT 
mice in the spine and in the femur (P= 0,980; P= 0,667).   
A significant decrease of total and cancellous volumetric tibial BMD (determined by pQCT) 
was observed after orc in the WT and the SRC-1 KO male mice, with a similar trend for 
cortical volumetric BMD (Table 3.5).  Estrogen treatment in the WT and the SRC-1 KO mice 
was sufficient to maintain total and cortical volumetric tibial BMD at the level of the sham 
mice.  However, the dose of E2 used was not sufficient to maintain tibial cancellous 
volumetric BMD in either the WT or the SRC-1 KO male mice (Table 3.5).  In contrast, in 
the female mice I observed that the dose of E2 administrated to the WT maintained (even 
increased) cancellous bone density but in the SRC-1 KO mice the cancellous bone did not 
respond to the estrogen treatment.   
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Figure 3.17. Percent changes in (A) lumbar spine and (B) femur BMD (both measured by DXA) in the WT and 
SRC-1 KO mice following sham surgery (open bars), orc plus vehicle pellets (solid bars), or orc and E2 pellets 
(shaded bars, 10 µg/kg/day) for 60 days.  The P-values for the main comparison (SRC-1 KO, orc + E2, versus 
WT, orc + E2) are as indicated.  ANOVA P-values for within group comparisons: spine WT, P = 0.03 and SRC-
1 KO, P < 0.001; femur WT, P = 0.01 and SRC-1 KO, P 0 0.003.  **P < 0.01 and ***P < 0.001 for direct 
comparison with the respective sham group. 
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Table. 3.5.  Percent Change of the volumetric BMD at the proximal tibial metaphysis, measured by pQCT (total 
vBMD, cancellous vBMD, and cortical vBMD) in the WT and SRC-1 KO male mice after either sham surgery, 
orc with vehicle pellet, or orc with E2 pellet (10 µg/kg/day) replacement for 60 days.  ANOVA P values for 
within group comparison are as indicated.  *, P < 0.05; **, P < 0.01; ***, P < 0.001 for direct comparison 
with the respective sham group.   
 
  
Total vBMD  
(% change) 
Cancellous vBMD  
(% change) 
Cortical vBMD  
(% change) 
  
 
Sham  2.55 ± 2.24 -14.84 ± 2.01 2.20 ± 0.39 
WT 
 
Orc + Vehicle -19.7 ± 5.03*** -39.71 ± 2.67*** -0.63 ± 0.89* 
  
 
Orc + E2 3.65 ± 9.94 -24.2 ± 7.88 6.11 ± 2.41 
 ANOVA 
 
 P = 0.004 P = 0.001 P = 0.006 
  
 
Sham  -0.4 ± 2.17 -15.96 ± 2.39 1.61 ± 0.89 
KO 
 
Orc + Vehicle -16.0 ± 1.95*** -34.59 ± 2.34*** 0.58 ± 0.95 
  
 
Orc + E2 -1.95 ± 6.2 -31.9 ± 3.17*** 7.02 ± 1.66** 
 ANOVA 
 
 P = 0.002 P < 0.001 P = 0.002 
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3.2.4 Effects of Orchidectomy and Treatment with Testosterone and 5α-DHT on the 
Skeletal Phenotype of SRC-1 KO Male Mice and WT Littermates 
3.2.4.1 DXA and pQCT 
 
To define possible deficits in androgen action on bone in the male SRC-1 KO mice, I 
compared the effects of sham surgery, orc with vehicle pellets, orc with testosterone 
replacement (7 mg/kg/day), or orc with 5α-DHT (5,5 mg/kg/day) on bone in WT versus 
SRC-1 KO mice.  The time of treatment was 60 days in this experiment, and BMD was 
measured at baseline and at the end of the experiment (see 2.13.4).  As shown in Figure 
3.18.A after orc the spine BMD (determined by DXA) was decreased significantly in the WT 
and SCR-1 KO mice.  Unexpectedly, the treatment with a dose of 7 mg/kg/day testosterone 
was not sufficient to prevent the loss of bone at the spine in the orc’d WT mice.  The 
treatment with testosterone resulted in the same loss of bone in both the WT and SRC-1 KO 
mice (P= 0,8).  In contrast the dose of 5α-DHT was sufficient to maintain the spine BMD in 
the WT mice and even further increase the spine BMD in the SCR-1 KO mice compared to 
the sham operated mice (Figure 3.18.A).   
Testosterone did not have any effect on the femur in the treated WT and SRC-1 KO mice 
(Figure 3.18.B).  The treatment with 5α-DHT was not sufficient to prevent bone loss in the 
femur of the WT mice.  However, in contrast, the dose of 5α-DHT prevented loss of bone at 
the femur in the SRC-1 KO mice in comparison with the sham mice (Figure 3.18.B).  There 
was even a significant increase in BMD compared to the 5α-DHT-treated WT mice.  The 
bone of the SRC-1 KO mice responded significantly better to the 5α-DHT treatment than the 
bones of the WT mice.  The bone of the SRC-1 KO mice seems to be more sensitive to 5α-
DHT than the bone of the WT mice.   
Figure 3.19 shows that the percent change of total, cancellous, and cortical volumetric tibial 
BMD decreased significantly after orc in the WT and SRC-1 KO mice.  The treatment with  
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Figure 3.18. Percent changes in (A) lumbar spine and (B) femur BMD (both measured by DXA) in the WT and 
SRC-1 KO mice following either sham surgery (open bars), orc plus vehicle pellets (solid bars), orc and T 
pellets (light shaded bars, 7 mg/kg/d), or orc and 5α-DHT pellets (dark shaded bars, 5,5 mg/kg/d) for 60 days.  
The P-values for the main comparison (SRC-1 KO, orc + T, versus WT, orc + T, and SRC-1 KO, orc + 5α-
DHT, versus WT, orc + 5α-DHT) are as indicated.  ANOVA P-values for within group comparisons: spine WT, 
P = 0.01 and SRC-1 KO, P < 0.001; femur WT, P < 0.001 and SRC-1 KO, P <0.001.  *P < 0.05, **P < 0.01 and 
***P < 0.001 for direct comparison with the respective sham group. 
 
testosterone did not have any effect on the total or cancellous volumetric BMD of the tibia in 
both the WT and SRC-1 KO mice.   
The cortical volumetric BMD showed a partial response to the testosterone treatment in the 
SRC-1 KO mice compared to the treated WT mice (Figure 3.19.C).  
The results from the percent change of the cancellous volumetric BMD in Figure 3.19.B 
show that the dose of 5α-DHT was sufficient to prevent the loss of cancellous bone in the 
WT mice.  The percent change was even significantly lower in the treated mice than the 
sham operated mice.  The 5α-DHT-treated SRC-1 KO mice were able to maintain BMD 
comparable to sham mice.  The direct comparison between the WT and KO mice did not 
show a significant difference in the response to 5α-DHT (Figure 3.19.B).   
The percent change of BMD at the femur suggested a better response of the cortical bone 
from the SRC-1 KO mice to the 5α-DHT treatment than the cortical bone of the WT mice.  
This notion could be confirmed with the cortical volumetric BMD measurements.  Figure 
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3.19.C shows that the dose of 5α-DHT was not sufficient to maintain the cortical BMD in the 
WT mice.  In contrast, volumetric BMD of the cortical bone was even higher in 5α-DHT 
treated SRC-1 KO mice than in the sham mice.  The cortical bone of the SRC-1 KO mice 
responded significantly better to the 5α-DHT treatment than the WT mice.   
The total volumetric BMD is a combination of the separate measurements of the cancellous 
and cortical bone in the metaphysis of the tibia.  Because of the better response of the cortical 
bone from the SRC-1 KO mice, the percent change of the total BMD of the SRC-1 KO mice 
was similar to the sham mice (Figure 3.19.A), however, differences of the percent change of 
the total BMD between the 5α-DHT-treated WT and SRC-1 KO mice did not reach 
significance.  In the WT mice the dose of 5α-DHT did not prevent the loss of total bone.   
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Figure 3.19. Percent changes in (A) tibial total (B) cancellous and (C) cortical volumetric BMD (all measured 
by pQCT) in the WT and SRC-1 KO mice following either sham surgery (open bars), orc plus vehicle pellets 
(solid bars), orc and T pellets (light shaded bars, 7 mg/kg/day), or orc and 5α-DHT pellets (dark shaded bars, 
5,5 mg/kg/day) for 60 days.  The P-values for the main comparison (SRC-1 KO, orc + T, versus WT, orc + T, 
and SRC-1 KO, orc + 5α-DHT, versus WT, orc + 5α-DHT) are as indicated.  ANOVA P-values for within 
group comparisons: total tibia WT and SRC-1 KO, both P < 0.001; cancellous WT and SRC-1 KO, both P < 
0.001; cortical WT and SRC-1 KO, both P = 0.03.  *P < 0.05, **P < 0.01, and ***P < 0.001 for direct 
comparison with the respective sham group. 
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3.2.4.2 Effect of Testosterone and 5α-DHT Treatment on Seminal Vesicle Weight 
The weight of the seminal vesicles from the WT and SRC-1 KO mice was significantly 
reduced after orc.  Figure 3.20 shows that the dose of testosterone just lead to about 50% of 
the sham surgery values in the WT and the SRC-1 KO mice.  In contrast, the treatment with 
5α-DHT resulted in an increase of the seminal vesicles weight of about two fold compared to 
the sham mice.  The seminal vesicles of the WT and the SRC-1 KO mice responded 
identically to the treatment with testosterone or 5α-DHT after orc.  
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Figure 3.20. Seminal vesicle weights in the WT and SRC-1 KO mice following either sham surgery (open 
bars), orc plus vehicle pellets (solid bars), orc and T pellets (light shaded bars, 7 mg/kg/day), or orc and 5α-
DHT pellet (dark shaded bars, 5,5 mg/kg/day) for 60 days.  The P-values for the main comparison (SRC-1 KO, 
orc + T, versus WT, orc + T, and SRC-1 KO, orc + 5α-DHT, versus WT, orc + 5α-DHT) are as indicated.  
ANOVA P-values for within group comparisons: WT and SRC-1 KO, both P < 0.001.  **P < 0.01, ***P < 
0.001 for direct comparison with the respective sham group.   
 72 
 Results  
3.3 Aromatase 
3.3.1 Expression of Aromatase in Human Cell Culture 
 
The expression level of the enzyme aromatase was determined by conventional PCR (see 
2.3.2) in different human cell lines.  Therefore, total RNA was isolated from the cultured cell 
lines (see 2.2.1.1).   
The enzyme aromatase was already expressed in undifferentiated hMS cells (see 2.1.).  The 
expression increased clearly within the first three days of differentiation in the standard 
differentiation media.  A further differentiation of the hMS cells for 7, 14, and 21 days to 
become osteoblasts did not result in an increased expression of the aromatase as compared 
with the differentiation after the first three days (Figure 3.21.A).   
In the same cells the expression of the estrogen receptor-α (ER-α) was examined as well, 
because the action of E2 is mediated by ER-α.  The undifferentiated hMS cells already 
express ER-α (Figure 3.22).  The lowest expression of ER-α was determined in the hMS 
differentiated for 21 days.   
To test whether the expression of the aromatase is regulated by E2, undifferentiated hMS 
cells were treated with vehicle, E2 (10-8 M), IL-1β (10 ng/ml), or the estrogen antagonist ICI 
182,780 (10-7 M) after the cells were cultured in steroid free medium (see 2.1).  The treatment 
of the hMS cells with E2 did not have any effect on the expression level of the aromatase.  
Only the treatment with ICI 182,780 decreased the expression slightly, the other treatments 
did not change the expression of the aromatase (Figure 3.23).   
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Figure 3.21.  Time course change of mRNA expression of (A) aromatase in hMS cells during the differentiation 
into mature osteoblasts.  hMS cells were cultured 0, 3, 7, 14, or 21 days in differentiation media.  The 
expression was assessed by RT-PCR.  The expression of GAPDH mRNA indicated that the sample loading and 
amplification for each of the preparation was approximately the same.  35 PCR cycles were used.   
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Figure 3.22. Time course of change of mRNA expression of ER-α in hMS cells during differentiation into 
mature osteoblasts.  hMS cells were cultured up to 21 day in differentiation media.  The mRNA expression was 
assessed by RT-PCR.  The expression of GAPDH mRNA indicated that the sample loading and amplification 
for each of the preparation was approximately the same.  40 PCR cycles were used.  
RT NC, Reverse Transcriptase negative control.   
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Figure 3.23.  Expression of aromatase mRNA in undifferentiated hMS cells treated with vehicle, E2, ICI, or IL-
1β for 24 h was assessed by RT-PCR.  The expression of GAPDH mRNA indicated that the sample loading and 
amplification for each of the preparation was approximately the same.  40 PCR cycles were used.  
PC, positive control; RT NC, Reverse Transcriptase negative control.  
 
The human osteoblastic osteosarcoma cell line SaOS2 was also examined for the expression 
of aromatase (see 2.1).  In the SaOS2 cell line the aromatase expression was low, when the 
cells were maintained in standard growth medium.  A very slight increase of aromatase 
expression was observed after the treatment with Dex and IL-1ß (Figure 3.24).  The cells also 
expressed ER-α with and without preincubation of Dex and IL-1ß (data not shown).  
However, the treatment with different doses of E2 (10-10- 10-7 M) and preincubation with Dex 
and IL-1ß did not change the expression of the aromatase in the SaOS2 cells (Figure 3.25).   
The conditionally immortalized, human osteoblastic FOB-ER9 cells which contain 
physiological concentrations of functional estrogen receptors were also examined for the 
expression of the enzyme aromatase (see 2.1).  The FOB-ER9 cells did not show aromatase 
expression regardless of the presence or absence of E2.   
 75 
 Results  
 
 
Sa
O
S2
 (+
)
H
2O
R
T 
N
C
Sa
O
S2
 (+
)
Sa
O
S2
 (+
)
Sa
O
S2
 (-
)
500
1000
500
1000
GAPDH
Aromatase
Sa
O
S2
 (+
)
H
2O
R
T 
N
C
Sa
O
S2
 (+
)
Sa
O
S2
 (+
)
Sa
O
S2
 (-
)
 
Figure 3.24.  Expression of aromatase mRNA was assessed by RT-PCR in SaOS2 cells.  The cells were 
maintained in growth media (SaOS2 (-)) or incubated with Dex for 72 h and IL-1β for the last 24 h (SaOS2 (+)).  
The expression of GAPDH mRNA indicated that the sample loading and amplification for each of the 
preparation was approximately the same.  35 PCR cycles were used. 
RT NC, Reverse Transcriptase negative control.  
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Figure 3.25.  Determination of the aromatase expression in SaOS2 cells in response to different concentrations 
of E2 (10-10- 10-7 M) by RT-PCR.  The cells were preincubated with Dex for 72 h and with IL-1β for the last 24 
h.  For comparison the expression of aromatase mRNA in cells without preincubation (SaOS2 (-)) was also 
determined.  The expression of GAPDH mRNA indicated that the sample loading and amplification for each of 
the preparation was approximately the same.  35 PCR cycles were used. 
RT NC, Reverse Transcriptase negative control. 
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3.3.2 Aromatase Expression and Activity in Rodent Cells and Bone 
UMR cells are preosteoblastic, and ROS17/2.8 cells have a relatively mature osteoblast-like 
phenotype (see 2.1).  RT-PCR analysis (see 2.3.2) of cDNA (see 2.2.1.1 and 2.2.2) from 
UMR and the ROS17/2.8 cells maintained in normal growth medium revealed the presence 
of aromatase and ER-α mRNA (Figure 3.26) in both cell lines.   
Furthermore, it was tested whether the expression of the aromatase in ROS17/2.8 cells will 
change in the presence or the absence of E2.  After a treatment with E2 (10-7 M), 4-
hydroxyandrostenedione (aromatase inhibitor), or ICI 182,780 (estrogen antagonist) for 24 
hours the expression of the aromatase did not change.  Only the treatment with Dex together 
with IL-1β led to a slight decrease of the aromatase expression in ROS17/2.8 cells (Figure 
3.27).   
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Figure 3.26.  Expression of aromatase and ER-α mRNA in rat osteoblastic cells.  Total RNA was extracted 
from (A) UMR cells and from (B) ROS17/2.8 cells.  The expression of GAPDH mRNA indicated that the 
sample loading and amplification for each of the preparation was approximately the same.  40 PCR cycles were 
used.  PC, positive control.   
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Figure 3.27.  Ros17/2.8 cells were treated with vehicle, E2, aromatase inhibitor (4-hydroxyandrostenedione), 
estrogen antagonist (ICI), or Dex plus IL-1β for 24 h.  The expression of the aromatase mRNA was assessed by 
RT-PCR.  The expression of GAPDH mRNA indicated that the sample loading and amplification for each of 
the preparation was approximately the same.  36 PCR cycles were used. 
RT NC, Reverse Transcriptase negative control 
 
Having established that the rodent cell lines (UMR and ROS17/2.8) express aromatase, it 
was of interest to determine whether long bones from rodents express aromatase and possess 
aromatase activity and whether the enzyme is regulated by estrogen.   
Therefore mRNA from long bones of sham and ovariectomized (ovx’d) rats was analyzed 
(see 2.2.1.2, 2.2.2 and 2.3.2).  All bone specimens from the ovx’d and sham operated rats 
(n=3) expressed aromatase but did not change in the two different conditions (Figure 
3.28.A).  Similar levels of aromatase mRNA between sham operated and ovx’d rats were 
observed using different numbers of RT-PCR cycles (Figure 3.28.B).  The analysis of 
GAPDH mRNA expression indicated that the sample loading and amplification for each of 
the preparations was approximately the same.  
Additionally, the aromatase expression in the long bones from 3 sham operated and 4 ovx’d 
mice was analyzed (see 2.2.1.2, 2.2.2 and 2.3.2).  The expression of the aromatase did not 
show a clear difference between the two different conditions (Figure 3.29.A). Of note, ER-α 
mRNA was detectable in all bone samples (Figure 3.29.B).  
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To investigate whether the aromatase activity was different from the expression level the 
aromatase activity was determined following the protocol from Ackerman et al. (1981) (see 
2.4).  The aromatase activity in bone samples from sham operated and ovx’d mice (C57BL/6, 
3 month) revealed similar values (sham: mean ± SEM, 0.61 ± 0.39 fmol/h/g bone; Ovx: 0.86 
± 0.50 fmol/h/g bone, n=3).   
In an additional experiment 9 months old CFW mice were used.  In these mice the aromatase 
activity was also clearly detectable (2.28 fmol/h/g bone). Moreover, the specific aromatase 
inhibitor, 4-hydroxyandrostenedione, markedly reduced aromatase activity in these mouse 
bone samples to 0.21 fmol/h/g bone, proving the specificity of the assay in assessing 
aromatase activity.   
In the present study I analyzed the expression and possible regulation of aromatase in rodent 
bone, but neither aromatase activity nor its expression level was regulated by E2. However, 
this study does indicate that human and rodent bone does express aromatase and the mice 
bones posse measurable aromatase activity. 
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Figure 3.28.  Total RNA was extracted from long bones of sham or ovx’d rats and the expression of aromatase 
mRNA was assessed by RT-PCR for (A) 34 cycles.  (B) 25, 28, and 32 RT-PCR cycles were used to detect 
possible differences between the sham and ovx’d rats.  The expression of GAPDH mRNA indicated that the 
sample loading and amplification for each of the preparation was approximately the same.  PC, positive control.  
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Figure 3.29.  Total RNA was extracted from long bones of sham and ovx’d mice and the expression of (A) 
aromatase and (B) ER-α was assessed by RT-PCR.  The expression of GAPDH mRNA indicated that the 
sample loading and amplification for each of the preparation was approximately the same.  34 PCR cycles were 
used. 
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4 Discussion 
While estrogens and androgens are clearly critical for regulating bone remodeling in both 
females and males (Khosla et al., 2002; Riggs et al., 2002), our understanding of steroid 
hormone signaling pathways in bone are far from complete.  In the presented work different 
aspects of estrogen and androgen action on bone were under investigation.   
4.1 Dose Response of Estradiol on Bone Versus the Uterus in Ovariectomized Mice 
In this study it was demonstrated that, in 6 month old C57BL/6 mice treated for 2 months, as 
little as 5 µg/kg/day of E2 delivered using slow release pellets completely prevented loss of 
cortical and cancellous bone without a stimulatory effect on the uterus.  Higher doses of E2 
further increased cortical and cancellous bone mass at various skeletal sites.  In contrast to 
these findings, in 3 month old mice treated for 1 month, the 5 µg/kg/day dose resulted in 
uterine hypertrophy but was ineffective in preventing loss of cancellous bone and higher 
doses of E2 were required to prevent bone loss.  Collectively, these results (1) provide data on 
the dose response of estrogen, using E2 pellets, on bone and the uterus; and (2) demonstrate 
that the relative effects of estrogen on these tissues depends on the particular experimental 
paradigm used.  The findings in the younger mice are similar to recent results of Andersson 
et al. (Andersson et al., 2003), who also found that there was a dramatic uterine response to 
very low doses of E2 in 2 month old mice, whereas both cancellous and cortical bone was 
less sensitive to the effects of estrogen in these mice.   
In this study it was found that whereas the 6 month old mice had significant decreases in 
bone mass at the spine (which contains predominantly cancellous bone) following ovx, they 
did not lose cancellous bone (but did lose cortical bone) at the tibial metaphysis following 
ovx.  Again, these findings were in contrast to the 3 month old mice, which lost cancellous 
bone at both the spine and tibial metaphysis following ovx (although the findings at the tibial 
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metaphysis did not achieve statistical significance).  Of note, whereas spine BMD was 
similar in the 6 and 3 month old mice (57,3 ± 1,0 mg/cm2 vs. 55,6 ± 2,0 mg/cm2, P = 0,39), 
cancellous BMD at the tibial metaphysis was significantly lower in the 6 month as compared 
to the 3 month old mice (Tables 3.1. and 3.2., 172,8 ± 3,52 mg/cm3 vs. 216.26 ± 8.14 
mg/cm3, P <0,001).  This suggests that cancellous bone at the tibia may be progressively lost 
with aging in these mice, so that by 6 months of age, ovx does not result in further loss of 
cancellous bone at this site, whereas cortical bone mass is still reduced following ovx 
(Halloran et al., 2002) (Zhou et al., 2003). 
Consistent with the here described findings in C57BL/6 mice, Gaumet et al. (Gaumet et al., 
1998) found that whereas the skeletal response to estrogen was similar in young (6 month) 
versus old (12 month) rats, the uterus of the old rats was much less responsive to estrogen as 
compared to the young rats.  It is also of interest that recent data indicate that very low doses 
of estrogen can prevent bone loss in elderly postmenopausal women without significant 
uterine stimulation (Cummings et al., 2003) (Utian et al., 1999).  Collectively, the here 
discussed findings and those other findings in rats and in humans indicate that whereas the 
skeleton retains sensitivity to estrogen throughout life, the uterus may become progressively 
less sensitive to estrogen with aging.  In light of the recent findings of the two studies from 
the Women’s Health Initiative (Rossouw et al., 2002) (Anderson et al., 2004) demonstrating 
adverse effects of estrogen plus progesterone on cardiovascular events and the risk of breast 
cancer, and an increased risk of stroke, decreased risk of hip fracture, and no effect on 
coronary heart disease incidence in postmenopausal women with prior hysterectomy after the 
treatment with conjugated equine estrogen, these data provide a further impetus to examine 
the effects of low doses of estrogen in elderly women, which may result in skeletal protection 
without adverse sequellae in other tissues. 
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In this study it was found that the subcutaneous implantation of slow release pellets is the 
most convenient and efficacious way to deliver estrogen to mice.  This avoids the handling 
and trauma associated with daily subcutaneous injections, as well as the possible peaks and 
valleys in serum E2 levels associated with injections (Edwards et al., 1992; Sims et al., 1996).  
However, it is possible that bone versus the uterus may respond differently to a constant, low 
dose of estrogen as provided by subcutaneous pellets versus the peaks and valleys associated 
with daily injections.  Indeed, previous studies have found that in mature rats subcutaneous 
injections of E2 (10 µg/kg/48h) resulted in a distinct increase in uterine weight (21%) 
compared to sham rats at doses that were less effective on bone, whereas similar doses of E2 
(18µg/kg/d) given by subcutaneous pellets lead to an increase in cancellous bone area with 
no increase of the uterine weight above the weight of the sham rats (Gaumet et al., 1998) 
(Sibonga et al., 1998).  Also of interest is the study from Erben et al. (Erben et al., 1998) in 
rats, where a dose of estrogen given by subcutaneous pellets (5.2 µg/kg/day) resulted in an 
increase in cancellous bone area with a concomitant decrease in uterine wet weight over the 
course of the treatment.   
However, also the time of exposure (1 month versus 2 month) to E2 may attenuate the 
response of the uteri.  This is probably due to down regulation/desensitization of the ER in 
the uterus.  The reports in the literature are very controversial regarding down- or up-
regulation of estrogen receptors by estrogen in rodent uteri (Medlock et al., 1991) (Bergman 
et al., 1992) (Rosser et al., 1993).   
In addition, the ratio between estrogen receptor alpha and beta and the homo- and 
heterodimerisation may also determine the downstream activities of estrogen in target tissues 
(Pace et al., 1997).  Also, it is not clear whether the sensitivity of the skeletal or uteri 
response is altered by continuous or intermittent administration of estrogen.   
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More recently it was demonstrated that an active genomic steroid response mechanism 
coexists with a nongenomic steroid effect in reproductive and nonreproductive tissues.  
Kousteni et al. (Kousteni et al., 2002) demonstrated an antiapoptotic effect of sex steroids on 
bone cells with physiologic concentrations (10-11 - 10-10 M).  They provided evidence that this 
is a nongenomic activation of a signaling pathway.  The nongenomic effect of sex steroids on 
cells from reproductive and nonreproductive tissues is a rapid mechanism which is mediated 
via the classical estrogen receptors which are localized in the membrane.  Data from other 
studies lead to the notion that a cross-talk between genomic responses to steroid hormones 
and cell surface receptor-mediated signal transduction pathways exists [for review see 
(Revelli et al., 1998)].  It is conceivable that different cell types in specific physiological 
situations use one or the other pathway to respond to sex steroids.   
As previously demonstrated (Tobias et al., 1991) (Bain et al., 1993) (Samuels et al., 1999), 
also this study showed that a very high dose of E2 (500 µg/kg/day) resulted in a dramatic 
increase in cancellous and cortical bone mass at the proximal tibia in the older mice.  By 
contrast, the spine did not demonstrate this sclerotic response to high dose E2.  Thus, there 
are important differences between the axial and appendicular skeleton in terms of the 
response to high dose estrogen.  The possible mechanism(s) for this are unclear, although it is 
of interest that studies with PTH have also shown different responses in axial versus 
appendicular sites.  In rats treated with PTH, the relative BMD gain was highest at the distal 
femur and proximal tibia and lower at the lumbar vertebrae (Kishi et al., 1998).  In mice, 
however, the PTH treatment augmented cancellous bones to a greater extend in the vertebral 
body than in the proximal tibia.  In contrast, the same treatment added cortical bone in the 
tibia, a highly mechanically loaded site, but not in the cortex of the lumbar vertebrae, a less 
loaded site (Zhou et al., 1994).  Moreover, in light of recent evidence that the skeletal 
response to mechanical loading may, at least in part, be mediated by ER-α (Lee et al., 2003), 
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it is possible that the differential sensitivity of axial versus appendicular sites to the sclerotic 
effect of high dose estrogen is related to weight bearing. 
An aim of ongoing research is to find compounds that have selective effects on the different 
target tissues of estrogen.  Two generations of these selective estrogen receptor modulators 
(SERMs) have already been generated.  The most notable from the first generation is 
tamoxifen, and from the second generation is raloxifene.  Tamoxifen possesses estrogen-like 
agonist activity on bone and simultaneously estrogen antagonist activity on the breast.  An 
unwanted side effect of tamoxifen was its estrogen-like action on the endometrium (Cosman 
and Lindsay, 1999) (Jordan and Morrow, 1999).  The National Surgical Adjuvant Breast and 
Bowel Project (NSABP) observed a 35% decrease of fractures of the hip, spine, and wrist 
and a 45% decrease in the incidence of breast cancer and a 2,5-fold increase in endometrial 
cancer with the treatment of tamoxifen (Fisher et al., 1998).  However, not all trials 
evaluating the preventive benefit of tamoxifen have shown similar positive results (Powles et 
al., 1998) (Veronesi et al., 1998).   
Raloxifene has estrogen-like effects on bone, lipids and the coagulation system, and estrogen 
antagonist actions on the breast and uterus.  Raloxifene has been approved for prevention 
and/or treatment of post-menopausal osteoporosis.  The Multiple Outcomes of Raloxifene 
Evaluation (MORE) study demonstrated an increase of bone density in femoral neck and 
spine and a reduced risk of vertebral fractures.  Raloxifene is similar to placebo in its uterine 
effects (Ettinger et al., 1999).  The mechanisms by which the same compound can exert 
estrogen agonist effects on one target tissue and antagonist effects on another still have to be 
clarified.  It was demonstrated that the estrogen receptor undergoes different conformational 
changes during the ligand binding.  Thus, the crystal structure of E2 bound to the estrogen 
receptor differs from that of raloxifene bound to the same receptor (Brzozowski et al., 1997).  
Mechanisms include differing interactions with various domains of the estrogen receptor, and 
tissue-specific recruitment of steroid receptor co-activators and co-repressors may underlie 
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some of the tissue-specific effects (Shang and Brown, 2002).  In light of the presented study 
it is important to test if also the SERMs show different responses at the different target 
tissues depending on the experimental conditions used.   
In summary, the study provides data on the dose response of bone versus the uterus to E2.  In 
addition, the study shows that the relative effect of estrogen on these tissues depends on the 
particular experimental conditions used.  The latter finding is of particular relevance in 
interpreting results of studies on new compounds (e.g. SERMs) with putative selective 
effects on bone versus reproductive tissues. 
4.2 Function of Steroid Receptor Coactivator-1  
SRC-1 was the first and one of the most important nuclear receptor coactivators to be 
characterized and cloned (Onate et al., 1995).  Estrogen signaling via the estrogen response 
element (ERE) is clearly dependent on SRC-1 (Onate et al., 1995); however, there is 
evidence that alterations in SRC-1 levels also influence the regulation by the ER of genes 
such as c-myc and IGF-I, which lack a classical ERE (Shang and Brown, 2002).  Whether 
estrogen signaling through nongenomic mechanisms also involves SRC-1 at some level is 
unclear at present, although it is of interest that Kousteni et al. (Kousteni et al., 2003) have 
demonstrated recently that estrogen regulation of the MAP kinase pathways eventually 
results in alterations in the activity of common transcription factors, such as Elk-1, CCAAT 
enhancer binding protein-β (C/EBPβ), cyclic adenosine monophosphate-response element 
binding protein (CREB), and c-Jun/c-Fos.  Since it is possible (and perhaps even likely) that 
one or more of these transcription factors also interact with SRC-1, loss of SRC-1 would be 
expected to alter estrogen signaling not just through classical EREs, but also through one or 
more of these other pathways.  Thus, a better understanding of the role of SRC-1 in 
mediating estrogen action on bone represents an important step towards further dissecting the 
overall mechanisms by which estrogen regulates bone metabolism. 
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The generation and characterization of SRC-1 KO mice by J. Xu and colleagues (Xu et al., 
1998) provided the first in vivo evidence that loss of this coactivator could result in estrogen 
resistance in reproductive tissues.  Using these mice in the here presented study, it was 
possible to characterize in detail the consequences of the loss of SRC-1 on estrogen and 
androgen action on bone of female and male mice.   
4.2.1 Effects of Loss of SRC-1 on the Skeletal Response to Estrogen in Female Mice 
Under basal conditions, SRC-1 KO mice represent a state of compensated estrogen resistance 
in a number of tissues: by maintaining a higher than normal E2 level, they exhibit normal 
reproductive function.  Yamada T. et al. also generated a SRC-1 knock out mouse line (SRC-
1 -/-) however, they used for the generation of the SRC-1 -/- mouse line a Cre-loxP system 
(using a ubiquitous CMV promoter) (Yamada et al., 2004).  In these SRC-1 -/- mice a stop-
codon was created in the middle of the bHLH-PAS domain at exon 5, predicting a truncated 
product.  Both mouse lines have a similar genetic background because they are intensively 
backcrossed into C57BL/6 mice.  The SRC-1 KO mice appear to have a relatively normal 
skeletal phenotype and BMDs, at least in young adulthood (~3 months of age).  Yamada T. 
also did not detect significant differences of bone density at 3 month of age between WT and 
SRC-1 -/- littermates of either sex under physiological conditions.  Significant differences 
were only seen at 6 month of age (Yamada et al., 2004).  It is speculated that with aging the 
compensatory elevation of sex hormone levels via a feedback mechanism becomes too weak 
to catch up with the decreased sensitivity to these hormones by the SRC-1 deficiency.   
However, by ovx the SRC-1 KO mice and using a dose of E2 (10µg/kg/day) that was clearly 
effective in preserving BMD in the WT mice, this study unequivocally demonstrated a 
profound defect in estrogen action on cancellous bone in the SRC-1 KO mice.  Similar 
results were also seen from Yamada et al. (Yamada et al., 2004).  Moreover, this defect could 
be overcome by using a 4-fold higher dose of estrogen, consistent with skeletal estrogen 
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resistance.  In contrast to this marked deficit in estrogen action in cancellous bone, the effects 
of estrogen (even at the low dose) on cortical bone in the SRC-1 KO mice were relatively 
well preserved.  This was established not only using cortical BMD measurements by pQCT 
(which has a voxel size of approximately 100 µm), but also by using what is generally 
considered the “gold standard” for such studies, µCT (which has a voxel size of 
approximately 20 µm).  Interestingly, while the low dose of estrogen was effective in 
preserving cortical BMD and thickness in the SRC-1 KO mice, in addition to having no 
effect in cancellous bone, this dose of estrogen also failed to alter uterine weight in the ovx’d, 
SRC-1 KO mice, while maintaining it at sham levels in the WT, ovx’d mice.   
Although a fairly high dose of E2 (~ 4-fold over physiological replacement) was used to 
overcome the deficit in estrogen action in cancellous bone in the SRC-1 KO mice, it is 
possible that lower doses (i.e. 2-fold or less) might also have been effective.  However, we 
wanted to establish, in principal, that the defect in estrogen action in the SRC-1 KO mice 
could be overcome, and further dose response studies are needed to establish the minimal 
dose of E2 that is capable of overcoming the deficit in estrogen action in these mice. 
There are several possible reasons why loss of SRC-1 results in a defect in estrogen action 
primarily in cancellous bone.  Cancellous bone does have a higher rate of turnover than 
cortical bone, and estrogen deficiency clearly has a greater impact on cancellous as opposed 
to cortical bone in WT female mice or, for that matter, in women (Riggs et al., 2002).  Thus, 
any defect in estrogen action (i.e. from loss of SRC-1) would be expected to perhaps be most 
evident in cancellous bone.  While this may be part of the explanation for the predominant 
defect in estrogen action in cancellous bone in the SRC-1 KO mice, a second possibility that 
involves potential differential interactions of SRC-1 with ER-α versus ER-β in bone cells 
should also be considered. 
In recent studies, it has been demonstrated that in osteoblastic cells, SRC-1 appears to 
preferentially enhance the transcriptional activity of either co-expressed ER-α and -β or ER-
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β alone, without significant effects on the activity of ER-α alone (Monroe et al., 2003).  By 
contrast, in non-osteoblastic (i.e. COS7) cells, this pattern is reversed, and SRC-1 
preferentially enhances the activity of ER-α to a greater extent than that of ER-β or 
coexpressed ER-α and -β.  The here presented findings also demonstrate that while the 
cancellous bone of the vertebrae contains both ER-α and -β, the cortical bone of the femur 
shaft contains almost exclusively ER-α.  Consistent with these findings, Onoe Y. (Onoe et 
al., 1997) also found that the cancellous bone of the vertebrae and distal femoral metaphysis 
in rats expressed much higher levels of ER-β than the cortical bone of the femoral shaft.  
Moreover, Bord et al. (Bord et al., 2001) examined ER-α and -β expression by 
immunohistochemistry in neonatal human ribs and, demonstrated that cortical bone 
contained predominantly ER-α, whereas cancellous bone contained immunoreactivity for 
both ER-α and -β. 
Collectively, the here described findings and the previous data indicate that cancellous bone 
contains both ER-α and -β [leading presumably to the formation of intracellular ER-α/β 
heterodimers (Pettersson et al., 1997)], whereas cortical bone primarily contains ER-α 
(resulting in the formation of ER-α homodimers).  Thus, based on previous studies (Monroe 
et al., 2003), the activity of the ER-α/β heterodimers in cancellous bone would be predicted 
to be most affected by loss of SRC-1, potentially explaining the predominant deficit in 
estrogen action in cancellous bone of the SRC-1 KO mice.  By contrast, the activity of the 
ER-α homodimers in cortical bone may not be significantly altered by SRC-1 deficiency, 
resulting in the relatively preserved responses to estrogen in cortical bone that were observed 
in the SRC-1 KO mice.  Interestingly, it was also found that in contrast to SRC-1, SRC-2 
does preferentially enhance the transcriptional activity of ER-α in osteoblastic cells to a 
greater extent than that of coexpressed ER-α and -β or ER-β alone (Monroe et al., 2003).  
This leads to the plausible prediction that estrogen effects on cortical bone would be more 
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impaired in the SRC-2 KO animals, with a relative preservation of estrogen action in 
cancellous bone in these mice, i.e. exactly the opposite of what was observed in the SRC-1 
KO mice.   
As noted earlier, the 10 µg/kg/day dose of E2 preserved uterine weight in the WT mice, but 
failed to do so in the SRC-1 KO mice.  Like cortical bone (Bord et al., 2001; Onoe et al., 
1997), the uterus contains predominantly ER-α (Couse et al., 1997), and this finding may 
seem at odds with the hypothesis that estrogen action in cortical bone was preserved in the 
SRC-1 KO mice because the previous in vitro studies had suggested that SRC-1 did not 
significantly enhance the transcriptional activity of ER-α in osteoblastic cells (Monroe et al., 
2003).  However, in those studies, Monroe et al. also found that in a kidney cell line, SRC-1 
did enhance the activity primarily of ER-α (Monroe et al., 2003).  While endometrial cells 
were not studied, these data indicate that the specific interactions of SRC-1 with ER-α versus 
-β are likely tissue specific, perhaps explaining why estrogen action is impaired in the uterus 
but preserved in cortical bone in the SRC-1 KO mice, even though both tissues primarily 
contain ER-α. 
The relatively selective loss of estrogen action which was observed in cancellous bone in the 
SRC-1 KO mice is consistent with other studies indicating that the cancellous and cortical 
compartments of bone are differentially regulated.  Thus, in contrast to the greater effects of 
estrogen deficiency on cancellous as opposed to cortical bone (Riggs et al., 2002), chronic 
PTH exposure leads to greater losses of cortical bone, with relative preservation (or even an 
increase) in cancellous bone (Parisien et al., 1990).  In addition, mice lacking plasminogen 
activator inhibitor 1 do not lose cancellous bone, but do lose cortical bone following ovx 
(Daci et al., 2000).  Finally, IL-6 KO mice have relatively well preserved cancellous bone 
volumes, but do have significant deficits in cortical bone (Poli et al., 1994). 
 90 
 Discussion  
In summary, the here presented results establish that loss of SRC-1 leads to a predominant 
defect in estrogen action in cancellous bone, with a relative preservation of estrogen effects 
on cortical bone.  However, the deficit in estrogen action in the SRC-1 KO mice can be 
overcome by using high doses of estrogen, consistent with estrogen resistance in bone.  The 
differential expression of ER-α and -β in cancellous versus cortical bone and the specific 
interactions of these receptor isoforms with SRC-1 may, in part, explain why cancellous bone 
is more susceptible to loss of SRC-1 than cortical bone.  In addition, these findings may also 
have significant implications for our understanding of the variability of skeletal responses to 
estrogen in humans, some of which may be due to alterations in the level or function of SRC-
1 in bone. 
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4.2.2 Effects of Loss of SRC-1 on the Skeletal Response to Estrogen in Male Mice 
SRC-1 KO male mice exhibit normal reproductive function and appear to have similar 
skeletal phenotype and BMDs like the WT littermates, at least in young adulthood (3-5 
months of age) (Yamada et al., 2004).  The examination of the function of SRC-1 in the male 
skeleton clearly showed the expected reduction of cancellous and cortical bone after orc at 
the different sites of the skeleton.  In agreement with the well preserved estrogen action on 
cortical bone (femur and cortical volumetric BMD) of the SRC-1 KO female mice treated 
with E2 there was no defect of estrogen action on the cortical bone of the SRC-1 male mice 
as well.   
In contrast to the findings in the female SRC-1 KO mice, the orc of the male SRC-1 KO mice 
and treatment with E2 delivered using slow release pellets (same pellets which were used in 
the female experiment; 10 µg/kg/day, body weight of 0,025 kg), did not show a defect of 
estrogen action on cancellous bone in the spine.  The response of the WT and SRC-1 KO 
male mice to the E2 treatment was similar.  Also the cancellous volumetric BMD of the tibial 
metaphysis was not different between the WT and SRC-1 KO mice. The dose of E2 was not 
sufficient to maintain the cancellous volumetric BMD in the metaphysis of the male SRC-1 
KO mice, but it was not sufficient in the WT mice either.  In the female SRC-1 KO mice it 
was suggested that the defect in response to physiological doses of E2 resulted from the 
preferred interaction of SCR-1 with ER-β or coexpressed ER-α and -β, which are mainly 
expressed in cancellous bone.  However, functional studies using sex steroid receptor 
inactivated mice (ERKO, BERKO) clearly show that ERKO male mice are totally 
unresponsive to E2, even at high doses (Sims et al., 2003).  This finding is consistent with 
previous results showing the lack of a bone phenotype in male BERKO mice, and the 
identical phenotypes of male ERKO and DERKO mice (Sims et al., 2002).  It was 
unequivocally concluded that in male mice ER-α but not ER-β is mediating the estrogen 
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action on bone, and SRC-1 is not necessarily important to respond to E2 and to maintain 
cancellous bone.   
Another possible explanation for the different findings in the cancellous bone of the female 
versus the male SRC-1 KO mice may be, in part, a gender-related difference of SRC-1 steady 
state mRNA levels (Misiti et al., 1998).  Significant gender- and area-specific differences in 
the expression of SRC-1 gene in the brain and pituitary under basal conditions and following 
acute stress were detected in rats by Northern blot analysis (Bousios et al., 2001).   
The very similar second member of the SRC family, SRC-2,  was overexpression twofold in 
the brain and testis of SRC-1 KO mice (Xu et al., 1998).  Thus, an up-regulation of the SRC-
2 may partially compensate for the loss of SRC-1 in the skeleton of the male mice, although, 
in the female SRC-1 KO mice, no significant difference in the level of the SRC-2 mRNA in 
bones from the WT and SRC-1 KO mice was detected.   
Our data suggest that because the regulation of estrogen action on bone is gender specific 
with ER-α as the main effector in male bone and the preferred interaction of SRC-1 with ER-
β, and a possible gender-related difference in the expression of the SRC-1 gene, the SRC-1 
KO male mice have no defect in estrogen action on bone, in contrast to the SRC-1 KO 
female mice.   
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4.3 Effects of Loss of SRC-1 on the Skeletal Response to Testosterone or 5α-DHT 
in Male Mice 
 
The effect of androgen can either be directly through the stimulation of androgen receptors 
(ARs) or indirectly through aromatization of androgens into estrogens and, thereafter, 
through stimulation of ERs.  However, the androgen 5α-DHT can not be aromatized to 
estrogen; thus, the effect of 5α-DHT is mediated through ARs.   
As shown in this study 5α-DHT was able to maintain cancellous BMD in the spine and in the 
proximal metaphysis of the tibia in the WT male mice.  The activation of the AR through 5α-
DHT regulates the amount of cancellous bone in male mice.  Recently, Vandenput et al. 
(Vandenput et al., 2002) demonstrated a better response of cancellous BMD compared to 
cortical thickness in WT rats after the treatment with 5α-DHT.  In contrast, no effect on 
cortical bone in WT mice was seen after the administration of 5α-DHT.  The cortical bone of 
the double knock-out mouse line ER-α-/-β-/- also did not respond to 5α-DHT, which leads to 
the presumption that the AR is not mediating the effect of 5α-DHT in cortical bone 
(Moverare et al., 2003).  This is in agreement with the findings that the conversion of 
androgens into estrogens is required for normal body growth in male rats, indicating that 
indirect effects of androgen, mediated by estrogens are also important (Vanderschueren et al., 
1997).   
The data of the SRC-1 KO male mice that the loss of SRC-1 has not impaired the effect of 
the administrated 5α-DHT in bone, and that 5α-DHT is even more effective in the bones of 
the SRC-1 KO mice especially in cortical bone was unexpected.  These data suggest that in 
cortical bone of WT mice SRC-1 functions as an inhibitor.  It can be speculated that in the 
presence of SRC-1 cortical bone is less protected against bone loss during the administration 
with 5α-DHT.  Contrary is the report from Yamada et al. (Yamada et al., 2004); they found 
that the restoration of the bone volumes in the SRC-1 -/- mice were limited to approximately 
one half due to insensitivity to 5α-DHT in the male mice.   
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SRC-1 interacts with ARs in vitro; however, this interaction is different from that with ER.  
Mediating the action of estrogen, SRC-1 interacts with the AF2 domain of the ER.  In 
contrast, at the AR it seemed that the N-terminal AF1 activation domain was most critical to 
activate transcription and that AF1 contributes all the activity of the receptor (Jenster et al., 
1991; Rundlett et al., 1990; Simental et al., 1991; Zhou et al., 1994).  These differences may 
differentially influence ligand-dependent activation of ERs and ARs such that SRC-1 
interaction with ERs is essential for estrogen action, but its interaction with ARs is not 
essential for androgen action; SRC-1 even inhibits the interaction of the AR with the ligand.  
In addition, SRC-1 has been reported to either increase or decrease AR activity in vitro 
(Ikonen et al., 1997; Takeshita et al., 1996).  The presented data suggest that SRC-1 has an 
inhibitory effect on mediating androgen action on cortical bone in male mice, and that the 
loss of SRC-1 leads to the abolition of the repressing action.   
In addition, other androgen receptor coactivators, for example ARA70, which is specific for 
androgen receptors and SRC-2, have been reported to interact and activate the androgen 
receptor and to mediate AR-mediated transactivation (Yeh and Chang, 1996).  Thus, it might 
be possible that these coactivators and other coactivators for androgen receptors are able to 
not only compensate for the loss of SRC-1 but also to be expressed and active more 
efficiently. 
Recent studies presented a positive effect of testosterone on bones in rats and mice 
(Vandenput et al., 2001; Vanderschueren et al., 2000).  The concentrations of administrated 
testosterone in these studies were in the same range or even lower than the dose of 
testosterone used in the here presented study.  However, the weight of the seminal vesicles of 
the WT male mice in this study was just restored to about 50 % of the weight from the sham 
operated mice after the treatment with 7 mg/kg/day of testosterone which is in contrast to 
other studies that determined a nearly 100 % restoration of the seminal vesicles after orc and 
testosterone treatment.  So far it is not clear why the 7 mg/kg/day of testosterone did not 
 95 
 Discussion  
restore the weight of the seminal vesicles in the WT mice and also did not prevent any loss of 
bone at the different sites of the skeleton.  One presumption is that the pellet did not have the 
expected dose of testosterone right from the beginning.  Because of the good experience with 
the slow release pellets in former experiments, there is not doubt on the general reliability of 
the pellets.  Because of the uncertainty whether the expected concentration of testosterone 
was administrated, no conclusions were drawn out of this part of the experiment.   
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4.4 Expression and Regulation of Aromatase in vitro and in vivo 
Previous studies in vivo have assessed the impact of circulating rather than local estrogens on 
bone cell activity.  However, more recent reports indicate that human osteoblast cells express 
the enzyme aromatase and therefore are able to generate estrogens from androgens locally 
(Nawata et al., 1995) (Sasano et al., 1997; Schweikert et al., 1995).  In this work, the 
differentiation of the hMS cells reveals that undifferentiated marrow stromal cells express 
aromatase and that there is a clear increase at the beginning of differentiation.  The 
expression of the aromatase did not further change during the remaining time of 
differentiation.  These data are supported by a previous study using SV-HFO (immortalized 
human fetal osteoblast) cells, which indicated that at the beginning of the differentiation the 
expression of aromatase increases, but there is no further increase during the remaining time 
of differentiation (Janssen et al., 1999).  However, the determination of the aromatase 
activity exhibits a significant decrease of activity by day 10 of culture (Janssen et al., 1999).  
Post-translational modifications, protein stability, or cofactor variations may be responsible 
for the described changes in aromatase activity.  Estrogen synthesis by osteoblasts may be 
partly dependent on osteoblast cell differentiation.  Probably the endogenous E2 synthesis is 
more important during the early proliferation phase of osteoblast development than during a 
more differentiated mineralizing phase.  Previous studies suggested that aromatase mRNA is 
undetectable in normal bone or bone marrow, but expression is induced under pathological 
conditions such as a fracture (Lea et al., 1997).   
It was of interest that treatment of ROS17/2.8 cells with Dex and IL-1β decreased the 
aromatase expression.  This is in agreement with the study from Eyre et al. (Eyre et al., 
1998).  They likewise reported a decrease of E1 and E2 production after the treatment with 
Dex.  In contrast, in human osteoblast cell lines a treatment with Dex increased the aromatase 
expression and activity, as demonstrated in this study in the osteosarcoma cell line SaOS2 
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and by other investigators (Tanaka et al., 1993) (Nawata et al., 1995) (Shozu et al., 2000).  
Why this and other studies see an opposite response to the treatment with Dex in human and 
rodent bone cell lines is not clear yet.  These observations show that there is a difference in 
the regulation of bone mass in humans and rodents.   
In this study, the expression of aromatase and ER in different human (hMS, SaOS2) and 
rodent (ROS17/2.8, UMR) bone cell lines was demonstrated, which opens the chance to 
elucidate the regulation of the aromatase in osteoblasts.  Yue et al. (Yue et al., 2001) 
demonstrated that the aromatase activity in breast tumors correlated inversely with tissue E2 
concentration.  Using long term estrogen deprivated MCF-7 cells they found a 4-6 fold 
higher aromatase activity compared to wild-type MCF-7 cells.  The re-exposition to estrogen 
containing medium decreased the activity significantly.  A recent report demonstrated that 
estrogen might serve as a negative factor for the regulation of aromatase activity in mammary 
glands of nonhuman primates.  Aromatase activity was increased significantly in the 
mammary glands after ovariectomy of the nonhuman primates and was reduced to the level 
in the intact animals by subsequent treatment with E2 benzoate (Nakamura et al., 1999).  In 
contrast, neither the aromatase expression nor activity of the different human and rodent bone 
cell lines, including SaOS2, hMS or ROS 17/2.8, nor the long bones of sham and 
ovariectomized mice and rats were regulated by E2.  Down regulation of aromatase by 
estrogen seems to be restricted to certain tissues because no effect was seen in human 
placental microsomes (Long et al., 1998) and in the here presented data with bone cell lines 
and bone tissue.   
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5 Summary 
1.  Estrogen is known to have important effects on both reproductive and non-reproductive 
tissues.  In this study it was demonstrated that an E2 dose of as little as 5µg/kg/d completely 
prevented loss of cancellous bone (at the lumbar spine and tibial metaphysis), and it had no 
stimulatory effects on the uterus in 6 month old C57BL/6 mice.  By contrast, when 3 month old 
C56BL/6 mice were administered the same doses of E2 and studied after 1 month; the 5 
µg/kg/d dose resulted in uterine hypertrophy, but was not able to prevent loss of cancellous 
bone.  These results, thus, a) provide data on the dose response for E2 effects on mouse bone; 
and b) indicate that the relative effects of E2 on bone versus the uterus are highly dependent on 
the particular experimental conditions used.  This issue needs to be considered in evaluating 
agents with potential “selective” effects on bone versus reproductive tissues. 
2.  Steroid receptor coactivator (SRC)-1 is an important nuclear receptor coactivator that 
enhances estrogen action in a number of tissues.  The presented study has established that SRC-
1 KO female and male mice have a comparable skeletal phenotype to their WT littermates at 3 
and 5 months of age.  The treatment of ovariectomized SRC-1 KO female mice with a 
physiological concentration of E2 led to a predominant defect in estrogen action in cancellous 
bone, with a relative preservation of estrogen effects on cortical bone.  However, the deficit in 
estrogen action in the female SRC-1 KO mice was overcome by using a higher dose of E2, 
consistent with estrogen resistance in bone.  The differential expression of the interacting 
nuclear receptors, ER-α and -β, in cancellous versus cortical bone and the specific interactions 
of these receptor isoforms with SRC-1 may, in part, explain why cancellous bone is more 
susceptible to loss of SRC-1 than cortical bone.   
3.  In contrast, the SRC-1 male mice lack the defect in estrogen action on bone.  These findings 
are consistent with a gender-related difference that in male mice ER-α but not ER-β is 
mediating the estrogen action on bone.   
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The treatment of SRC-1 KO male mice with 5α-DHT resulted in a significant better response 
of the cortical bone from the KO male mice compared to the WT mice.  The findings lead to 
the suggestion that in male WT mice SRC-1 might inhibit the action of 5α-DHT on bone.   
4.  Peripheral tissues including bone are dependent on circulating active sex steroids, but also 
synthesize estrogen from circulating C19 precursor locally.  The conversion of the precursors 
to estrogen is mediated by aromatase.  In this work it has been shown that human and rodent 
osteoblastic cells at different stages of differentiation express aromatase.  Furthermore, the 
expression and activity has been demonstrated in bone tissues of mice and rats.  Although a 
regulation of the aromatase by E2 was reported by other investigators in certain tissues, such 
as breast tissue and mammary glands, I did not find a change of aromatase expression and 
activity in the various bone cell lines and bone tissue under estrogen deficiency and estrogen 
exposure.   
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6 Zusammenfassung 
1.  Östrogene haben einen wesentlichen Einfluß auf reproduktive und nichtreproduktive 
Gewebe.  In der vorliegenden Studie konnten wir zeigen, daß die niedrigste verwendete 
Östradiolkonzentration von 5 µg/kg/Tag den Verlust von spongialem Knochen (in den 
Lendenwirbeln und der tibialen Metaphyse) verhinderte und keinen anregenden Einfluß auf 
das Uterusgewebe in 6 Monate alten C57BL/6 Mäusen hatte.  Im Gegensatz dazu kam es bei 
3 Monate alten Mäusen des gleichen Stammes nach einer einmonatigen Behandlung mit den 
gleichen Östradiolkonzentrationen bereits bei 5 µg/kg/Tag zu einer Hypertrophie des Uterus, 
ohne jedoch den Verlust von spongialem Knochen zu verhindern.  Die Ergebnisse dieser 
Studie liefern a) Daten über die Östradiol-Konzentrationsabhängigkeit der Knochen von 
Mäusen, und b) weisen darauf hin, daß die Effekte von Östrogenen am Knochen gegenüber 
dem Uterus stark abhängig sind von den jeweilig gewählten experimentellen Bedingungen.  
Dieser Aspekt muß bei der Beurteilung von möglichen Knochen- oder Uterus-selektiv-
wirkenden Mitteln beachtet werden. 
2.  Der Steroidrezeptor Coaktivator (SRC)-1 ist ein wichtiger Zellkernrezeptor-Coaktivator, 
der in verschiedenen Geweben den Einfluß von Östrogenen verstärkt.  In der vorliegenden 
Studie wurde gezeigt, daß weibliche und männliche SRC-1 KO Mäuse im Alter von 3 und 5 
Monaten einen ähnlichen skeletalen Phänotypen besitzen wie die WT Mäuse.  Die 
Behandlung von weiblichen SRC-1 KO Mäusen mit einer physiologischen 
Östradiolkonzentration führt zu einem Defekt der Östrogenwirkung in spongialem aber nicht 
in kortikalem Knochen.  Dieses Defizit der Östrogenwirkung in den weiblichen SRC-1 KO 
Mäusen kann durch die Behandlung mit einer höheren Östradiolkonzentration aufgehoben 
werden.  Die unterschiedliche Expression der mit SRC-1 interagierenden Zellkernrezeptoren, 
ER-α and -β, in spongialem und kortikalem Knochen und die bevorzugte Interaktion der ER-
α/β heterodimere und ER-β homodimere mit SRC-1 in Knochenzellen könnte eine mögliche 
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Erklärung liefern, warum spongialer Knochen anfälliger ist gegenüber dem Verlust von SRC-
1 als der kortikale Knochen.   
3.  Im Gegensatz dazu weisen die männlichen SRC-1 KO Mäusen keinen Verlust der 
Östradiolwirkung am Knochen auf.  Diese Ergebnisse stimmen mit dem geschlechter- 
bedingten Unterschied der Rolle des ER-β im Knochen von männlichen gegenüber 
weiblichen Mäusen überein.   
Die Behandlung männlicher SRC-1 KO Mäuse mit 5α-DHT führte zu einer signifikant 
höheren Knochendichte im kortikalen Knochen der KO Mäuse im Vergleich zu den WT 
Mäusen.  Dieses Ergebnis läßt darauf schließen, daß in WT Mäusen SRC-1 möglicherweise 
hemmend wirkt auf die Bindung von 5α-DHT an den SRC-1-Rezeptor Komplex und dadurch 
das Androgen nicht dem Verlust von Knochenmasse entgegenwirken kann.   
4.  Periphere Gewebe, wie der Knochen, sind abhängig von zirkulierenden Steroidhormonen, 
aber auch von der lokalen Östrogensynthese aus 19 C-Atom Androgenen.  Diese Androgene 
werden durch Aromatisierung in Östrogene umgewandelt, und dieser Schritt wird von dem 
Enzym Aromatase katalysiert.  In der vorliegenden Arbeit wurde gezeigt, daß menschliche 
Osteoblastenzelllinien und Osteoblastenzelllinien von Nagetieren, die sich in verschiedenen 
Differenzierungsstufen befinden, das Enzym Aromatase exprimieren.  Des weiteren konnten 
wir die Expression und die Aktivität in Knochengeweben von Mäusen und Raten 
nachweisen.  Obwohl für einige Gewebe, wie Brust und Milchdrüse, berichtet wurde, daß die 
Aromatase von Östrogenen reguliert wird, konnte in den untersuchten Zelllinien und 
Knochengeweben keine Änderung der Expression oder Aktivität unter Östrogendefizienz 
oder –behandlung beobachtet werden. 
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7 Abbreviations 
 
1,25 (OH)2D3 1α,25 dihydroxyvitamin D3 
3-D three dimensional  
A adenine 
AD activation domain 
AF-1 activation function 1 
AF-2 activation function 2 
AMV avian myeloblastosis virus 
AR androgen receptor 
AscP ascorbic phosphate 
βGP β-glycerolphosphate 
BERKO ER- β knock-out  
BFR bone formation rate 
bHLH basic helix loop helix 
BMC bone mineral content 
BMD bone mineral density 
bp base pairs  
BS bone surface 
BV/TV bone volume/measured tissue volume (%) 
C cytosine 
Cbfa 1 core-binding factor alpha-1 (transcription factor) 
CBP/p300 transcription factor 
cDNA complementary DNA 
Ci Curie 
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cm centimeter 
cm2 square centimeter 
cm3 cubic centimeter 
CO2 carbon dioxide 
CSS charcoal stripped serum 
CV coefficient of variation 
DERKO ER- α/β double knock-out 
Dex dexamethasone 
5α-DHT 5α-dihydroxytestosterone 
dNTPs 2’- desoxyribonucleotid-5’-triphosphates  
DXA dual energy X-ray absorptiometry 
E estrogen 
E1 estrone 
E2 estradiol 
E3 estriol 
ERKO ER- α knock-out  
ER-α estrogen receptor-α 
ER-β estrogen receptor-β 
EtOH ethanol 
g gram 
g gravity unit 
G guanine 
h hour 
HAT histone acetyl transferase 
HCl hydroxychloride 
HI-FBS heat inactivated fetal bovine serum 
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kb kilo bases 
KCl potassium chloride 
KO knock-out  
L leucine 
l liter  
µ micro: x 10-6 
µm micrometer 
M molar 
MCS-F macrophage colony-stimulating factor 
mg milligram  
MgCl magnesium chloride 
min minute 
ml milliliter 
mm millimeter 
mM millimolar 
mRNA messenger ribonucleic acid  
n nano: x 10-9 
n number of animals per treatment group 
N2 nitrogen 
NADPH nicotinamide-adenine dinucleotide phosphate, reduced 
nm nanometer (Wavelength)  
NR box nuclear receptor box 
ºC Celsius  
OPG Osteoprotegerin 
PAS Pas/Arnt/Sims 
PBS phosphate buffered saline 
 105 
 Abbreviations  
PEG polyethylenglycol 
pmol picomol 
pQCT peripheral quantitative computer tomography  
PTH parathyroid hormone 
RANK receptor for activation of nuclear factor kappa B 
RANKL receptor for activation of nuclear factor kappa B ligand 
RID receptor interaction domain 
RNA ribonucleic acid 
rpm rounds per minute 
SCR-1 steroid receptor coactivator 1 
SCR-2 steroid receptor coactivator 2 
SCR-3 steroid receptor coactivator 3 
 sec second  
SEM standard error 
SERMs selective estrogen receptor modulators 
T thymine 
Tb.N trabecular number(mm-1) 
Tb.Sp trabecular separation (µm) 
TbTh trabecular thickness (µm) 
TRAP tartrate resistance acid phosphatase 
UV ultra violet light 
WT wild type 
X any other amino acid 
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